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Depression is one of the most common diagnosis in psychiatry. The largest epidemiologic 
study1 to date reported the 12-month prevalence of depression in Europe as 6.9%, while it has been 
estimated that over 340 million people worldwide are suffering from depressive symptoms. These 
data should explain increasing regards on depressive illness as a major public health problem: World 
Health Organization Global Burden of Disease Survey anticipates that, by the year 2020, major 
depression will be second only to ischemic heart disease in the amount of disability experienced by 
sufferers2. Burden of depression not only depends on the high health care costs, but it also consists 
of the remarkable human and social costs. This is firstly due to the significant tendency to recurrences: 
it is reported that over two thirds of patients may present recurrences. Exactly the likelihood of a 
relapse after the first episode has been calculated around 50%, with an increase to 90% after a second 
episode3. Although it classically takes an episodic course, depression becomes chronic in 15-25% of 
sufferers4. In longitudinal studies one of five depressed patients kept to have a major depressive 
episode two years later the onset, while up to 7% were still depressed ten years later5,6. 
The treatment of patients with depression represents then a real public health challenge. Since 
in clinical studies on major depressive disorder (MDD) symptomatic remission increases the 
probability of recovery, a successful treatment of depression should aim to the complete resolution 
of symptoms. Clinical experience and available data clearly indicate that the majority of individuals 
with major depression (MD), receiving guideline-concordant and measurement-based care, do not 
achieve a fully and sustained remission with current antidepressants.  
In the most recent and largest naturalistic study on therapy of MDD, the Sequenced Treatment 
Alternatives to Relieve Depression Study (STAR*D), only half of patients responds to an initial 
antidepressant trial and an even smaller percentage, around 30%, achieves clinical remission7. 
Moreover, remission rates decrease, and subsequent relapse rates increase, as a function of 
the number of failed acute treatments. After a first unsuccessful medication trial in STAR*D, only 
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25% of patients remitted with a second, 14% with a third8. As a consequence, despite the wide range 
of therapeutic options, treatment resistance is quite common in clinical practice and accounts for an 
important part of human suffering and social burden caused by depressive illness9,10. To characterize 
patients with depressive syndrome, who are unable to achieve a significant therapeutic response after 
multiple antidepressant trials, the concept of Treatment Resistant Depression (TRD) has been 
introduced in the 1970s. It has been calculated that almost half of the cost and burden caused by 
depression is likely to be attributable to TRD11,12. Compared to those who do not develop treatment 
resistance, patients with TRD experience a more severe and protracted course of illness, being more 
likely to have physical and/or psychiatric comorbidity, to suffer significant social and functional 
impairment and to attempt suicide 9-16. 
The study of underpinnings and characteristics of TRD is then to be considered as crucial in order to 
improve the aid of depressed patient. With every new wave of novel treatment, concerns regarding 
the definition and the impact of TRD are expounded and followed by the outlining of its growing 
prevalence, clinical and social costs. It has been observed that this approach risks to reify the concept 
of TRD, since, while successive new therapies fail to make an impression, a significant proportion of 
depressed patient keep to develop a form of TRD, with a chronic, unremitting course, high levels of 
disability and mortality17. 
 
 
1.1 Definition of treatment resistance 
 
Since the first appearance in the literature, in 1974, of the term treatment resistant depression 
(TRD)18,19, a large amount of study has been published on this topic, maybe stimulated by the 
increasing availability of new antidepressant drugs. The extensive set of research knowledge remains 
however difficult to read, because of the extreme heterogeneity of conceptual definitions and 
operative criteria proposed in literature3,16,20,21. An operational, validated and systematic definition of 
TRD is still lacking. In psychiatry the underpinnings of a therapeutic resistance may be more complex 
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to determine than in other areas of medical practice. Treatment resistance generally may be defined 
by the responsiveness of the causative pathogenic mechanism to therapy, the underlying pathologic 
process, or the level of disease process. For depression, modelling on these factors therapeutic 
resistance become less manageable by the paucity of knowledge regarding the pathological basis of 
disease. Instead, many attempts to conceptualize and quantify treatment resistance in depression are 
based on a medication failure approach, referring to the number and/or the type of treatments, 
administered to the patient without a clinically meaning effect on depressive syndrome. As already 
observed, the lacking of consensus regarding what determines a failed treatment may account for 
most variability in defining TRD.  
A method commonly used in research settings to evaluate treatment outcomes involves the 
assessment of the presence and the severity of depressive symptoms following the completion of an 
adequate treatment course. The measurement of depressive symptoms is made by using a 
standardized and validated depression rating scale, such as Hamilton Rating Scale for Depression 
[HAM-D] or Montgomery-Asberg Depression Rating Scale [MADRS]22,23. Besides the type of 
adopted rating scale, disagreement still remains across clinical studies and expert opinions, 
concerning the degree of change in depression severity, required to differentiate a failed treatment 
from a successful therapy. The debate on this point revolves around the concepts of “response” and 
“remission”. In research response to treatment is usually defined in categorical terms as a reduction 
in baseline symptomatology of 50% or more24.The reference to a specific cut-off scores may be 
discussed, because it may be less relevant or clinically significant for patients with extremely high 
depression scores at baseline17. Moreover, no real distinction is drawn between the various symptoms 
of depression. This means that a quantitatively similar response can reflect improvement across very 
different symptoms domains; for example, reduction of symptoms such as insomnia and fatigue may 
be taken as equivalent to improvement in a different set of symptoms such as suicidal ideation and 
psychomotor retardation. As before reported, expert opinions and therapeutic guidelines for 
depression agree in indicating the resolution of depressive symptoms or remission as the ideal 
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outcome of an efficacious antidepressant treatment. The importance of remission rests of evidence 
that following acute treatment remitters, compared to patients who have response, but keep to present 
residual sub-syndromic symptoms, have better function, a better prognosis, a more stable, enduring 
state24. There is less consensus regarding the operative definition of remission. Among the few 
clinical trials, that have evaluated this parameter, some authors have described remission as the 
complete absence of depressive symptoms, while others proposed specific cut-off point on standard 
depression rating scale (≤7 on HAM-D; ≤10 on MADRS).   
Further heterogeneity, among the medication failure-based definitions of TRD, concerns the number 
of unsuccessful trials, required to assess therapeutic resistance. In a large review of controlled 
antidepressant trials, fourteen of the studies included defined treatment resistance as failure to 
improve after at least 1 antidepressant medication, while 24 studies defined it as failure to respond to 
at least 2 antidepressant trials20. Although the majority of authors still considers a minimum number 
of two trials as criteria for TRD, data from longitudinal sequential antidepressant studies indicate that 
usually three trials are needed before the majority of patients responds to the point of remission25. In 
2007 The European Union’s Committee for Proprietary Medicinal Products (CPMP)26 tried to bring 
order among the variety of definitions of TRD, suggesting to consider depressed patient as “therapy 
resistant, when consecutive treatments with 2 products of different classes, used for a sufficient length 
of time at an adequate dose, fail to induce an acceptable effect”. To point out that the concept of 
pharmacological class corresponds to the mechanism of action, while no further information has been 
offered to specify what means “a sufficient length of time” and “adequate dose”.  
Thanks also to the sustain of the CPMP indications, this approach to define TRD, centred on the 
criteria of failed response to two adequate antidepressant trials, with different mechanism of action, 
has been gained a growing consensus in literature, still accompanied by some both methodological 
and conceptual objections. A first argument of debate is the implicit assumption that the lack of 
response to two drugs of different molecular class represents a condition of greater severity than the 
non-response to two trials with antidepressants of the same class. The second issue concerns the 
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postulate that derives from superior effectiveness of the switch between different classes of 
antidepressants compared to intra-class switch (this postulate could affect treatment decisions). Both 
of these assumptions are not clearly supported by the evidence derived from clinical trials13,20,21. 
 It is also debated when a treatment should be considered adequate. In many treatment guidelines, 
antidepressant trial is defined as adequate, if the agent is administered for at least 4 weeks at the 
maximum tolerated dose, although a considerable variation remains, related to treated patients’ 
population and to prescribed class of antidepressant20. It has been observed, moreover, that treatment 
adequacy may refer to the overall quality of management, with a range of additional factors that 
influence treatment response, including whether the patient is accepting the diagnosis and the need 
of treatment17. These factors are important because they determine treatment compliance and like 
antidepressant therapy parameters vary according to type of depression.  
The dichotomous approach, implied in the medication failure-based model of therapeutic resistance, 
appears to contradict clinical observations on the dimensional nature of the TRD. As pointed out by 
some authors27,28, TRD may be better conceptualized as a heterogeneous descriptor, capturing those 
with differing types of depression and with differing causes and reasons for treatment non response.  
It has been proposed also a conceptualization on the model of the “spectrum”, i.e. on the line of a 
continuum that extends from the failure to respond to a single antidepressant, up to the lack of 
response to different classes of antidepressants and finally to strategies of "strengthening", including 
the ECT29,16.  
Prevalent definitions of TRD, basing on the medication failure method, whereby pharmacological 
trial is implicated in any non-response, exclude considerations about psychological therapies 
eventually made by the patient33.However, in clinical practice they encounter often patients with 
depressive syndromes, whose development is strictly dependent by psychosocial or psychological 
factors and then which may better respond to differing treatment strategies such as a psychotherapy, 
rather than to pharmacotherapy. In these cases, any failure to respond to an antidepressant treatment 
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may not be considered as a real treatment resistance, but viewed, as Parker et al. observed, as a 
diagnostic “paradigm failure” 34. 
 
1.2 Staging of TRD 
 
The lacking of universally shared defining criteria did not help the development of a staging 
model of treatment resistant depression (TRD), contributing to the variety of system proposed, none 
of them have been systematically examined, verified for reliability, or validated for prospective 
predictive utility. An ideal system for staging TRD should be able to distinguish between depressive 
symptoms according to their level of resistance to drug treatment, predict the likelihood of remission 
in subsequent trial and address the choice of further treatments; the existing staging models satisfy 
partially these requirements, as it may ascertain by the following descriptions. 
 
Thase and Rush staging model 
The staging method, developed by Thase and Rush in 199735, has been considered for a long 
time a landmark in the research setting of treatment resistant depression (TRD). It consists of 5 levels 
of treatment resistance, distinguished by the number and type of antidepressant therapies, including 
ECT, that have been identified as treatment failures (see figure 1). Its main characteristic is a 
hierarchical methodology, according to which medications used at the higher order of treatment 
resistance are implicitly assumed to have superior efficacy33,28,20. However, studies of efficacy do not 
report meaning difference among pharmacological classes of antidepressant. Evidence from literature 
do not support further hierarchical assumption, implied in this model: the superiority of switching 
within antidepressant class as opposed to switching to different class36,37. As some authors have been 
observed, this staging may be referred to a sequenced therapeutic algorithm, in which medication is 
prescribed in a certain sequence, progressing from a single medication to augmentation therapy and 
culminating in the use of ECT9. This appears in contrast with what occurs in clinical practice, where 
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treatment is prescribed in an individual way, with informed negotiation rather than in a predetermined 
sequence, in which ECT is the treatment of last resort. 
 
European staging method 
In 1999 Souery et al.38 have proposed an alternative staging method, that includes both a 
classification and a staging approach to treatment resistant depression (TRD). Depressed patient can 
be classified as: 1) non responder, if he has failed to respond to one antidepressant trial, of adequate 
dose and duration; 2) experiencing TRD, after failing to respond to 2 trials of different 
antidepressants, of adequate dose and duration; 3) having chronic resistant depression (CRD), when 
a major depressive episode persists for more than a year, despite several adequate antidepressant trials 
(see figure 1).  
The staging of treatment resistance is relied on matching failed response to specific class of 
medication, with duration of treatment trials. This model offers some advantages, compared to the 
Thase and Rush one. The first concerns the defining of TRD, on the basis of the failure of two 
adequate antidepressant trials, from different classes, that is the criteria, generally adopted in 
psychiatric literature on TRD33. A second advantage is related to the consideration given to the role 
of the duration of illness in treatment resistance20,39. The European method includes evaluations on 
the treatment adequacy: a trial can be considered adequate, when administered at an adequate dose, 
for a period of 6 to 8 weeks. Despite these added benefits, it may be also contested that the model 
does not address symptom severity or medication augmentation strategies and assumes the 
differential effectiveness of medications, without a clear evidence9,39. 
 
Massachusetts General Hospital staging method  
In the Massachusetts General Hospital staging method (MGH-S), treatment resistance is 
primarily staged on the number of failed antidepressant trials, including into evaluation also 
optimization, combination and augmentation strategies13. The MGH-S assigns 1 point for each prior 
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antidepressant medication, administered at an adequate dose, for a period of at least 6 weeks; 0,5 
points are assigned for each optimization, combined and augmentation trial; a special weight is given 
for failure of treatment with ECT, which receives a score of 3 (see figure 2). The MGH-S may be 
appreciated for the flexibility to incorporate as many medications as required in gauging degree of 
resistance. Moreover, data from a small-size study demonstrated that the MGH-S scores had a 
significantly greater utility to predict non-remission compared with Thase and Rush method14. To 
point out, however, that the small size of sample included in the study does not allow the 
generalizability of the findings39. Finally, it has been discussed the validity of the special weight given 
to treatment with ECT, since there is no clear evidence that resistance to ECT may be a sign of 
resistance to antidepressant drugs9. 
 
Maudsley Staging Method 
The Maudley Staging Method (MSM)9 is the most recent staging model and is based on a 
conceptualization of treatment resistant depression (TRD) as a continuum of various dimensional 
factors, that may contribute to its occurrence and maintenance. The multidimensional staging method, 
that allows to measure treatment resistance, is based on both therapeutic and clinical variables (see 
figure 2). The therapeutic variables include number of treatment failures, use of augmentation 
strategies and administration of ECT. The clinical factors are illness duration and symptom severity. 
The main advantage, offered by the MSM, is just the multifactorial assessment of TRD, with an 
adequate accounting for the nature and course of depressive illness. Symptom severity and disease 
duration both have been associated with decreased efficacy and persistence of depressive residual 
symptoms40-43. Regarding treatment factors, the MSM does not differentiate between therapeutic 
failures of different medication classes, thus not making assumptions concerning a hierarchy of 
efficacy among the classes of antidepressants. First evidence from literature may encourage the use 
of the MSM as staging model for TRD: two small-scale study have produced promising results 
regarding its predictive validity9, while in a more recent study, that examined the long term outcome 
11 
of TRD patients, based on duration episode, higher MSM scores were associated with the persistence 
of the depressive episode44.  
  
Despite their numerous differences, the above mentioned methods shared the reference to the 
medication failure, as the fundamental parameter to measure the resistance to treatment. Less 
considerations are given to the illness characteristics, with the only exception of the Maudsley Staging 
Method, which includes also symptoms severity and illness duration.  
It has been observed that the management of patient with TRD often relies on a clinician’s 
“constrained” approach, which derives from the limitations of the current paradigm for 
conceptualizing and modelling the depressive disorders34. In fact, most theoretical and research 
considerations of TRD are referred to the viewing of depression as a single disorder with various 
degree of severity and chronicity. Little attention is devoted to depressive sub-type or 
pathophysiology. Parker et al.45-47 proposed an alternative model, based on sub-typing depression by 
clinical features and pathophysiology. This model posits three principal expression of depression: 
psychotic, melancholic and non-melancholic; the first two would be characterized as a more distinct, 
essentially neurobiological disorders, with specific clinical features. The non-melancholic subtype 
shows instead a dimensional structure, which is furtherly sub-divided on the basis of its aetiological 
determinants, presuming to be principally life-event stresses and personality styles. The clinical utility 
of this model may be sustained by the evidence of a differential effectiveness of antidepressant 
treatments across the depressive sub-types. Data from literature indicate that psychotic depression is 
most likely to respond to combination of antidepressant and antipsychotic medications or ECT48,49; 
physical treatments are more efficacious than others (i.e. psychotherapy) also for melancholic sub-
type50, with some evidence of gradients of effectiveness across narrow-action and broader action 
antidepressant drug classes51. For the non-melancholic presentation evidence are less clear, however 
some data may suggest that SSRIs antidepressant are particularly useful to patients, with personality 
style, marked by emotional dysregulation52, that MAOIs are superior to TCAs among patients with 
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reverse neurovegetative symptoms53, that cognitive behavioural therapies may be more useful to 
patients with social-phobic or dependent personality traits54.   
 
1.3 Management of treatment-resistant depression 
 
In the aid of depressed patient with history of non-response to multiple antidepressant 
medications, the clinician may run the risk of labelling the patient, with a hasty diagnosis of treatment 
resistance. This risk can be prevented by systematically reviewing the common reasons for treatment 
failure and then differentiating between true treatment resistance and pseudo-resistance. 
The term pseudo-resistance was firstly utilized to nominate the case of failure of antidepressant trials, 
referable to inadequate dosage of medication and/or duration of treatment55. Most recently, every 
condition in which the non-response to therapy is attributable to factors external to treatment’s action 
is defined as pseudo-resistance20. Still today the inadequacy of treatment in terms of dosage or 
duration, is recognized as a common cause of unsuccessful therapy21,56. Data from the literature57 
suggest that less than half of depressed patients receives adequate antidepressant treatment with 
standard doses for a period of time long enough to induce a clinically significant effect. Prescribed 
dose and period of administration have to be included in the assessment of the treatment outcome. As 
regards to the adequacy of dosage, depression treatment’s main  guidelines consider appropriate a 
tricyclic antidepressant (TCAs) trial with no less than 250-300 mg/day of imipramine (or equivalent), 
while for  monoamine oxidase inhibitors (MAOIs), a trial of 90 mg/day of phenelzine (or equivalent) 
is to be considered as adequate58,59. For selective serotonin reuptake inhibitors (SSRIs) and new-
generation antidepressants (SNRI, NARI, NaSSA) no precise criteria to define the appropriate dose 
of the drug are still available, since the relationship between dose-plasma level and response to 
therapy is still not clear and needs further clinical and pharmacological studies60. Low serum levels 
of antidepressants may also depend on unusual pharmacokinetic problems, as a consequence a correct 
evaluation on the adequacy of dosage should account for eventual effects on the metabolism of drug 
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by potential variability factors such as age, gender, body weight, general physical condition, genetic 
characteristics and drug interactions.  
The role of patient’s genotypic characteristics on the antidepressant treatment outcome has been made 
evident in recent years by the findings of several studies, which examined genes involved in the 
metabolism of drugs and xenobiotics such as the transmembrane transporter ABCB1, better known 
as P-glycoprotein, isoenzymes CYP2D6 and CYP2C19 cytochrome P45061.  For example, in a 
Swedish study62, comparing patients, treated with nortriptyline, who presented two different 
genotypes of CYP2D6 (fast and slow metabolizers), the authors found that about 90% of non-
responder patients was in the rapid metabolizer subgroup. However, the role of the cytochrome P450 
on the outcome of treatment is still controversial, in facts, the results of recent surveys63,64 did not 
confirm an association between genotype for the isoenzymes CYP2D6, 2C19 and response to 
antidepressant trials.  
Evaluation of treatment adequacy is also based on the period of time, during which the medication 
has been administrated. Most of clinical controlled studies have considered as optimal a period of 4 
to 6 weeks; however, these studies have been sponsored by the pharmaceutical industry, in order to 
determine statistically significant differences between the drug and the placebo13,15,65. In treatment 
resistant depression (TRD) the standard period of four weeks should be prolonged before assuming 
the ineffectiveness, particularly in special populations. Several studies65-67, indeed, have shown that, 
in partial-responder patients, clinical remission of depression may be reached by prolonging the 
duration of the trial over 10 weeks. Some authors16,68 remarked that in elderly depressed patients, the 
treatment may be taken for at least 12 weeks prior to appreciating a significant improvement.   
Treatment compliance is another crucial aspect: according to some data, up to 20% of failed 
antidepressant trials are attributable to the lack of patient adherence to therapeutic requirements. 
However, this percentage is likely to be significantly underestimated, because usual care data from 
primary care settings indicate that only 40% of patients take adequate antidepressant dosage, during 
the first six months of treatment. Treatment compliance may be favored.by psychoeducational 
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interventions centred on the information about the characteristics of the disorder, the nature of the 
symptoms, the course, the discussion on the effects of drugs, the expected results and the duration of 
treatment20,21 69. 
Finally, inadequate diagnostic assessment is to be listed among the external factor of potential 
resistance to treatment. Diagnosis that may lead to incorrect labelling as treatment resistant 
depression, include mood disorders secondary to substance abuse or medications (including 
benzodiazepines), depression secondary general medical conditions such as endocrine disorder 
(hypothyroidism, Cushing's disease) or neurological illness (multiple sclerosis, parkinsonism)21,15. 
The reviewing of diagnosis may also include the symptomatic characteristics of depression, in order 
to exclude the presence of unrecognized depressive subtypes, which might benefit from different 
therapeutic approach, as discussed before. 
 
1.4 Predictors of treatment resistance in depression 
 
The influence of certain clinical and sociodemographic variables on treatment outcome has 
been widely debated. However, most of the studies evaluated factors associated to the non-
response to a single antidepressant trial, while few studies tried to correlate clinical and 
sociodemographic patient’s characteristics to the treatment resistance, defined as a condition of 
failed response to multiple antidepressant trials70. Moreover, heterogeneity of guidelines and 
criteria for defining treatment resistant depression (TRD) contributed to make the findings of these 
studies difficult to compare and systematize. As such, the clinical and sociodemographic variables, 
identified in literature as associated to TRD, should be viewed as risk factors of treatment 
resistance vs actual predictors. 
 
Psychiatric comorbidity 
Psychiatric comorbidity is often reported in the literature as one of the major clinical risk 
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factors of resistance to antidepressant treatment15,39,70. The presence of a comorbid psychiatric 
disorder may be missed or inadequately treated. Psychiatric disorders that are most frequently 
diagnosed in comorbidity with depressive syndrome include anxiety disorders, substance abuse 
and personality disorders. The presence of comorbid anxiety disorders seems to affects 
antidepressant treatment outcome. Several studies have reported that depressed patients with 
comorbid anxiety disorder, in particular panic disorder, responded poorly to treatment and tend to 
have a slower response to medication and an incomplete remission of symptoms15,71,74. Recent 
large dataset specifically focusing on treatment resistant depression (TRD) may assign to the 
anxious comorbidity also the role of predictor of treatment resistance. In a European multicentre 
study of 200770, Axis I diagnosis of anxiety disorder was found in 39.3% of patients with TRD. 
Anxious comorbidity increased by 2.6 fold the risk of resistance to antidepressant treatment. 
Parker and Graham27, in their study on a large sample of depressed patients, divided in three 
treatment resistance (TR) groups (“low”, “medium” and “high”), by the number of failed 
antidepressant trials, found that the high TR group, compared to the two others, had a greater 
incidence lifetime of anxiety disorders, specifically obsessive-compulsive disorder, agoraphobia 
and social phobia.   
Substance abuse may also complicate the management of TRD75. Even a moderate consumption 
of alcohol can contribute to refractoriness to antidepressant therapy76. The frequent association 
between TRD and substance abuse may depend on two main aspects. First, acute and chronic 
effects of substances may cause or worsen depressive symptoms and affect compliance. Second, 
persistence of depressive symptoms increases the likelihood of a substance abuse77. Unfortunately, 
the sparse literature on this topic is not able to guide usefully the clinician. Expert opinions suggest 
that aggressive multimodal treatment is most effective for these patients15. 
The role of comorbidity with personality disorders seems rather controversial. Data77-79 
from some studies have indicated that depressed patients with personality disorders are less 
responsive to antidepressant treatment and have a worse prognosis in terms of long-term outcome. 
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However, these evidence derived from studies on tricyclic antidepressants and have not been 
confirmed by subsequent paper80-82. Personality disorders have been found to correlate with an 
earlier age of onset of depression, which has been associated with the degree of treatment 
resistance15,39,69. Therefore, the presence of a comorbid personality disorder could influence the 
relationship between lifetime duration of illness and treatment resistance.  
Other psychiatric disorders that may be comorbid with depression and affect treatment outcome 
include eating disorders. Comorbidity with eating disorders has been reported in 37% of depressed 
patients84 and is to be consider important risk for non-compliance, because of fears of weight gain 
associated with some antidepressant therapies. 
 
Somatic comorbidity 
The co-presence of a medical condition in depressed patient may contribute to treatment 
resistance, especially if it is not diagnosed or adequately managed. Unrecognized physical 
pathology is detectable in about one half of patients admitted for depression and it may affect the 
outcome of the treatment, interfering with both medication efficacy and patient compliance15,84.  
In the study of Parker and Graham27, higher level of treatment resistance correlated to a higher 
number of lifetime medical conditions. Longitudinal studies85,86 have suggested that major 
depressive disorder patients with physical comorbidity may have a greater risk for a chronic course 
of depression or for incomplete recovery, as compared to MDD patients without physical illness. 
However, evidences from further surveys seem to contradict the correlation of physical 
comorbidity with resistance to antidepressant treatment. For example, Miller et al.87 failed to show 
any relationship between cardiovascular risk factors and poorer MDD outcome, while Papakostas 
et al.88 have found no difference in response between treatment resistant depression patients with 
physical comorbidity and those without concomitant somatic illness. One study90 on 671 elderly 
patients found that certain comorbid medical disorders, such as arthritis and circulatory problems, 
but no other general medical conditions, were related to a worse outcome with respect to 
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depression symptoms. These findings would support the view that only specific forms of medical 
comorbidity (e.g., diabetes, coronary artery disease) may have even greater chances of being 
associated with poorer outcome.    
One of the most studied medical comorbidity in depressed patients is thyroid disease: subclinical 
hypothyroidism forms has been observed in more than half of depressed patients with 
refractoriness to treatment90.  
 
Severity symptoms 
Numerous treatment and follow up studies have associated severity of depression with 
resistance to therapy. It has been found that severely depressed patients are less likely to respond to 
antidepressants, psychotherapy and electroconvulsive therapy (ECT), while they are exposed to a 
greater risk of residual symptoms and relapse41,42,91,92. The association of severity of illness with 
treatment outcome has been demonstrated for both the severity determined by diagnosis according to 
specified criterion or measured by dimensional scales15. Other common clinical indicators of severity, 
such as the long duration of the episode, the high recurrence, the number of hospitalizations, early 
age of onset and a positive history of failure of previous antidepressant therapies, have been identified 
as risk factors for resistance to antidepressant therapy93,15.  
The current literature on treatment resistant depression have emphasized the relationship between 
illness duration and treatment outcome: there are numerous evidences on association of greater 
chronicity or longer duration of depressive episode with increased unresponsiveness to antidepressant 
treatment13,39. Lifetime duration of depressive illness, which is referred to early age of onset, has been 
found to have a positive relationship with refractivity to psychopharmacological treatments and 
higher rating of treatment-resistant severity73,94.  
A poor response to treatment may also be correlated with qualitative aspects of symptomatology, such 
as the presence of melancholic features, psychotic symptoms or suicidal thoughts13,15,93. The presence 
of suicidal ideation may affect the outcome of antidepressant treatment: two studies that compared 
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TRD patients with non-resistant depressed patients, found that the presence of suicidal intentions was 
more frequent in patients with refractoriness to treatment95, 96. 
 
Socio demographic factors 
The investigations on the role of sociodemographic variables have mainly produced unreliable 
results. Although age and gender have been described as potential risk factors for treatment resistant 
depression (TRD), literature data on these socio-demographic variables are not conclusive. Regarding 
the relationship between age and TRD, many studies have indicated that older patients are at higher 
risk of non-response to antidepressant treatments and delayed remission97. However, it has been 
observed that many of the diagnosis of TRD in older patients may hide conditions of pseudo-
resistance98,99. Various diagnostic and treatment related factors, such as physical illness comorbidity 
and inadequate antidepressant medication trials may in fact contribute to insufficient response in 
geriatric patients.  Some previous studies had associated female gender to poor response to treatment, 
but the most updated data have instead reduced the weight of gender, pointing out however in subjects 
of female gender a decreased likelihood of response to particular classes of antidepressants such as 
TCA s15,100,101.  
 
 
1.5 Treatment-resistant depression and bipolar diathesis 
 
One variable that is often mentioned as an important risk factor for treatment resistant 
depression (TRD) is undiagnosed or unrecognized bipolar disorder (BD) both in its more restricted 
or “classic” conceptualization as well as in a more broadly defined “soft bipolar spectrum” 
conceptualization102. Evidence from several studies seem to support this belief: the non-response to 
antidepressants can be associated with an “occult” bipolarity and, on the other hand, the presence of 
bipolar clinical features or of bipolar prospective course often underlie the refractoriness to treatment 
antidepressants103-105. 
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In a sample of TRD unipolar patients, followed up for one year, Sharma et al. (2005)106 found that 
59% of the patients developed a diagnosis of Bipolar Disorder I or II, while more than half of the 
sample were subsequently classified having bipolar spectrum disorder. Overall, about 80% of the 
sample showed significant evidence of bipolar diathesis106. The relationship between resistance to 
antidepressant treatment and evolution of bipolar disorder was confirmed by the findings of multiple 
studies: in a survey of follow-up of depressed patients initially diagnosed with unipolar depression, 
the probability of conversion to bipolar disorder was statistically higher among patients with 
resistance to antidepressant therapy compared to responder patients102. These results are in line with 
data from even more recent study104 on a population of “unipolar” depressed patients, that have 
demonstrated the association between a drug history of poor response to antidepressant treatment and 
the probability of evolution in bipolar disorder. In the multicentre Treatment-Resistant Depression 
Project (TRES-DEP), Dudek et al.105 identified bipolarity, as assessed with the Mood Disorder 
Questionnaire (MDQ) and the Hypomania Checklist (HCL- 32), as a risk factor for resistance to 
antidepressant treatment in patient with major depressive episode. Based on these evidences, some 
authors have advanced the hypothesis that, at least in some cases, resistance to treatment could 
recognize an iatrogenic origin, or could be a consequence of an uncorrected prescription of 
antidepressant drugs in a patient with unrecognized bipolar diathesis108-110. In support of this 
hypothesis, it should remember some of the effects of antidepressant therapy, usually described in 
bipolar depressed patients, but also commonly observed in resistant unipolar depression. For 
example, the phenomenon of "wear-off" consists in the gradual loss of the therapeutic efficacy of the 
antidepressant, after the initial response in the acute phase of the treatment, with the consequent return 
of depressive symptoms in the later stages of maintenance and/or prophylaxis phases. 
“Refractoriness” instead includes the progressive loss of therapeutic efficacy in subsequent trials109 
and is considered a sign of the onset of bipolar diathesis, just like the onset, coinciding with 
assumption of antidepressant, of symptoms of thymic sphere (irritability), psychomotor (restlessness) 
and cognitive (ideas acceleration) dimensions that tend to set up a framework of attenuated mixed 
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state or mixed depressive syndrome110,111. 
However, the relationship between bipolar diathesis and response to antidepressant is still debated. 
Ghaemi109 tried to argue the fundamental role played by soft bipolarity in the resistance to 
antidepressants concluding that, as showed by the results of the studies of effectiveness STAR*D and 
STEP-BD, the misdiagnosis of bipolar symptoms within depression is the main cause of the limited 
efficacy of antidepressants in the treatment of depression. On the opposite side, Perlis et al.112 claim 
that the association of non-response to antidepressants with some symptoms, that are also signs of 
bipolarity, such as irritability and psychotic-like events, does not necessarily mean that the bipolar 
spectrum is correlated with resistance to treatment, but it may imply that the lacking of response is 
correlated to these specific symptomatic aspects. 
It is still debated if the prescription of antidepressants (also in combination with mood stabilizers) 
may be associated with an increased incidence of suicidal behaviour in depressed patients with bipolar 
diathesis. It has been supposed that in the first weeks of treatment, antidepressants are more effective 
on the motor symptoms than on the cognitive dimension and mood. Therefore, in patients who have 
risk factors for suicide in the short term (anxiety, insomnia, dysphoria, agitation) antidepressant 
therapy could result in a boost to the action and then worsen the risk of anticonservative behaviors113. 
According to McElroy et al114, in these patients there would be a "partial" manic switch, where only 
the psychomotor component, but not the cognitive dimension (which remains "fixed" on the 
experiences of incurability, hopelessness and pessimism), shows a sudden and abrupt change, 
corresponding to an attenuated mixed state. Moreover, antidepressants treatments may lead to a 







1.6 Therapeutic options for treatment resistant depression (TRD) 
 
Several therapeutic strategies have been delineated in literature to relieve depression, after the 
failure of multiple adequate trials. The options include pharmacological interventions, 
psychotherapies and physical methods of neurostimulation. However, the evidence, supporting these 
strategies, derives mainly from pilot and/or open-label studies, while few controlled trials have been 
conducted to assess their efficacy.   
 
1.6.1. Pharmacological strategies 
If one or more antidepressant trials fail to achieve an adequate response and no specific reason 
can be identified and corrected, the clinician can choose among different strategies: 
a. increasing the dose and/or the duration of the current treatment (optimization); 
b. replacing the first antidepressant drug with a second belonging to the same pharmacological 
class or to a different class (switching intra-class or inter-class) 
c. combining at least 2 antidepressants, that have well-established efficacy (combination); 




Especially if the treatment outcome is sub-optimal, i.e. insufficient to qualify as remission, the next 
step may consist in optimizing current therapy, with the increase of drug dose and/or additional week 
of administration. It has been demonstrated for TCAs, MAOIs and SNRIs (venlafaxine), that doses 
in the high therapeutic range are more effective than doses in the low therapeutic range116,117. Dose 
escalation would be a reasonable option in case of insufficient response to one of these drugs at the 
22 
standard dose, as long as the patient has not developed side effect to treatment and has a positive 
attitude to the drug in question. For venlafaxine, dose increase may also modify action profile, from 
a predominate serotonergic action at lower doses to a noradrenergic stimulation118. However, the 
principle “more is better” holds for some, but not all antidepressants. Clinical trials have consistently 
shown high-dose treatment with SSRIs to be no more effective than treatment at the standard dose4. 
A SPECT study found that administration of paroxetine, at the dose of 20 mg/die already causes 
blockage of roughly 80% of serotonin transporters in the CNS, without any further increase in patients 
treated with higher dose of the drug (mean, 47 mg/die)120. In case of inadequate response to SSRIs, 
then, dose increase may be not a useful option, considered the relatively flat dose-response curve, 
within their therapeutic dosing range.  
Treatment optimization can include also the prolongation of the period of drug administration; six 
weeks of treatment appears to be an adequate duration for the majority of patients, but there is a 
subgroup of patients, who may benefit from a longer course of treatment. The following variables 
have been associated with delayed remission: chronicity (both as duration of current episode and 
number of previous episode), older age, psychiatric and medical comorbidity, symptom 
severity35,121,122.  The rationale for increasing antidepressants treatment’s duration comes also from 
the observation that a substantial number of depressed patients would be "late responders": 53% of 
patients treated with TCAs, in fact, respond beyond the sixth week of antidepressant treatment123. 
However, optimal treatment duration before switching or augmenting medication is a matter of debate 
since minimizing time to remission is considered an important clinical objective. Although in case of 
non-response or partial response usual and recommended practice is to reconsider treatment regimen 
after 4-8 weeks, a strong correlation has been demonstrated between symptom improvement at 2 and 





After the failed or insufficient response to an antidepressant treatment, a viable option is 
represented by the replacement of the antidepressant with another drug belonging to the same class 
(intra-class switch) or a different one (switch inter-class). Compared to augmentation or combination 
strategies, switching to another monotherapy offers simplicity, avoiding the administration of 
different kinds of drugs (the main reason for poor compliance), fewer adverse effects and may be 
more cost-effective. Disadvantages include the possibility of withdrawal symptoms, patient’s 
reluctance to take a new drug, time lag between the beginning of the new medication and treatment 
response, the necessity of a period of cross-titration or wash-out. A large number of open-label 
trials124-128 and a few double-blind, controlled trials129 suggest that the switching is effective in 
achieving a response in approximately 40% to 60% of cases. It is frequently recommended that 
patients who do not respond to one class of antidepressant have to be switched to a class with a 
different mechanism of action. Even though the recommendation appears to have merit, to date, there 
is no clear evidence that between-class switching increases the likelihood of achieving either response 
or remission compared to within-class switching. Data from previous studies seemed to indicate the 
benefit of switching from SSRI to antidepressant with a dual action; for example Poirier and Boyer 
(1999)130 found higher response and remission rates switching from paroxetine to venlafaxine, rather 
than the inverse switch (52%-42% vs 33%-20%), while other studies reported the increase of 
likelihood of therapeutic response, switching from an SSRI to a TCA (16.5 to 48.5 %), despite the 
higher percentage of drop-outs related to side effects129,131. Recently, the results from the STAR*D 
may not support any advantage for between-class switching. In the study, patients who failed to 
respond to citalopram had similar response rates after within-class switching to sertraline (27%) when 
compared to between-class switching to either bupropion (26%) or venlafaxine132. Moreover, it is to 
consider that, regarding tolerability, within-class switching to sertraline was well-tolerated, even in 
the sub-group of patients who reported poor tolerability to their initial course of treatment with 
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citalopram. Finally, there is also evidence, showing the validity of switching intra-class for SSRI, 
both in terms of increased response rate and better tolerability. In the meta–analysis, carried out by 
Ruhè et al.30, it is reported that switching to a second SSRI was effective in achieving response and 
well tolerated in the 50% of patients who do not respond to a first SSRI and in the 70 % of patients 
who discontinue a first SSRI for side effects. 
 
c. Combination  
The use in association of two antidepressant drugs is included among the available therapeutic 
strategies for patients with treatment resistant depression (TRD). This option may be considered 
particularly in case of partial response or non-response, without significant side effects, since the 
offered advantages of avoiding the loss of the therapeutic benefits of previous treatment and reducing 
the risk of withdrawal symptoms. Further advantage is the possibility to expand the range of action 
of the treatment, acting on different neurotransmitter systems, associated with different 
psychopathological dimensions118. By contrast, combination therapy may reduce patient compliance, 
induce the risk of drug interactions and finally, increase economic costs. Combining drugs to achieve 
a dual-action is the most common use of combination strategy and may be accomplished by 
combining a SSRI with a noradrenergic reuptake inhibitor (nortriptyline, desipramine) or SNRI, such 
as venlafaxine or duloxetine. An open-label study and a small double-blind trial31,32 have 
demonstrated higher response rate with fluoxetine-desipramine combination therapy than with 
fluoxetine or desimipramine treatment alone. Evidence of efficacy from controlled randomized trials 
are available only for combinations between a reuptake inhibitor (i.e. SSRI, SNRI, or TCA) and a 
presynaptic auto-receptor blocker (mianserin, mirtazapine, trazodone). Such combinations have been 
found to be more effective in inducing response, compared to single antidepressant associated with 
placebo, in several randomized clinical trials4,72,93,94. It is unclear from the available evidence4 
whether each of the two drugs combined should be administrated in the standard dose, used for 
monotherapy, or whether lower doses might suffice. It is presumed, though not yet documented, that 
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standard doses are more effective. The STAR*D study tested the use of SSRI (citalopram) in 
combination with bupropion, whose antidepressant effect may be mediated by the stimulation of 
dopaminergic central neurotransmission132. This combined therapy, compared to the augmentation of 
citalopram treatment with buspirone, was found to be modestly more effective in achieving remission 
(39% vs 33%), but better tolerated, with significantly lower attrition due to adverse events (12% vs 
21%)132. Finally, it is to consider that some authors and some guidelines suggest antidepressants 
combination as the first choice in patients with severe forms of depression. The rationale for this 
choose relies on the need of an "aggressive" treatment of depression, that can promote a rapid and 
complete resolution of symptoms, minimizing the risk of residual symptoms and the correlated risk 
of early relapse133. 
 
d. Augmentation  
The augmentation strategies rely on the addition of a non-antidepressant drug to the current 
treatment regimen. Benefits of augmentation therapy include rapid onset of action, no withdrawal 
symptoms, and continued use of the antidepressant that produced an initial, although inadequate 
response. Disadvantages may be possible drug-drug interactions, increased costs and additional 
medication, which may affect patient compliance. A wide array of drugs has been used to augment 
the efficacy of antidepressants in patients with various stages of treatment resistant depression (TRD), 
though the choice of first-line augmentation agents continues to be debated134. Current evidences from 
literature in fact do not generate clear conclusions regarding the efficacy of available treatments, 
because they include mainly open-label studies, small sample sizes randomized trial and a paucity of 
direct comparison among agents135. Main augmentation strategies are listed below: 
Lithium - The use of lithium as augmentation agent began in the 1980s and today again is the most 
commonly studied strategy. However, the majority of efficacy studies was open-label and/or did not 
use placebo control, included patients with imprecise TRD staging and tested augmentation of highly 
heterogeneous antidepressant therapy. Only 10 double-blind, placebo-controlled trials may be 
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identified in literature and have found that the response rate was significantly higher with lithium 
augmentation (45%) than with placebo. In STAR*D study augmentation with lithium was compared 
to thyroid hormone (T3) in patients, with diagnosis of nonpsychotic major depression, who have failed 
12 weeks of prospective treatment with both citalopram and a second course of treatment that 
consisted of either switching to a second antidepressant class or combination with bupropion or 
buspirone60. Remission rates were 16% with lithium augmentation and 25% with T3 augmentation, 
though the difference was not significant. Evidence from continuation-phase studies is sparse but 
suggests that lithium augmentation should be maintained in the lithium–antidepressant combination 
for at least 1 year to prevent early relapses136. Concerning outcome prediction, single studies have 
reported associations of better outcome rates with more severe depressive symptomatology, 
significant weight loss, psychomotor retardation, a history of more than three major depressive 
episodes, a family history of major depression, and/or other indicators of bipolar diathesis137. Further 
argument in favour of lithium augmentation is the preventive effect on a high risk for suicide, as 
indicated by previous/current suicide attempts and/or family history of suicide. The independent 
benefit of lithium in reducing suicidality has been consistently shown, not only in multiple analyses 
of published efficacy trials138, but also in a prospective, controlled trial with the reduction of 
suicidality as its primary end point. However, a recent multi-centre, randomized trial139, carried out 
about patients with TRD and an episode of suicide attempt in the previous 12 months, have reported 
preliminary data, that may not demonstrate efficacy of lithium in reducing risk of completed suicide 
and deliberate self-harm. Lithium augmentation has generally well tolerated with all antidepressant 
classes and the combination of lithium with antidepressants has not been associated with serious side 
effects, though many of these data derive from augmentation of TCAs140.   
Triiodothyronine (T3)- Thyroid hormone augmentation strategies have been extensively evaluated. 
Meta-analyses of multiple studies, mostly poor designed and notably underpowered, have found the 
use of T3 augmentation to be associated with a significant increase in the likelihood of response to 
antidepressants60. However, the quality of the evidence on T3 augmentation strategy is poor4: only a 
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small subsample of patients included in the studies met criteria for TRD. Moreover, many clinicians 
are hesitant in prescribing thyroid hormone, because of the risk of interfering with thyroid function 
in euthyroid individuals and inducing adverse events such as tachycardia, nervousness and insomnia.  
Second generation antipsychotics (SGA)- The use of atypical antipsychotics as add-on in treatment 
of major depression relies on mounting evidence and is quickly growing among clinicians. Results 
from two meta-analysis demonstrated that adjunctive atypical antipsychotics are significantly more 
effective than placebo with an approximate two-fold higher odds of achieving remission141,142. Such 
findings appear to be confirmed by recent meta-analysis on comparative efficacy and tolerability of 
augmentation agents in TRD, which have indicated quetiapine and aripiprazole as the best evidence-
based options for augmentation therapy135. However, the adverse event profile of SGA still remains 
potential limitation for their prescription. Compared to placebo atypical antipsychotics have higher 
odds for discontinuation due to akathisia (i.e. aripiprazole), sedation (i.e. quetiapine), abnormal 
metabolic laboratory results and weight gain (i.e. quetiapine, olanzapine)143. Controlled data on 
efficacy in recurrence prevention are still lacking in literature; a double-blind comparison of 
continuation therapy with citalopram plus placebo versus citalopram plus risperidone found no 
additional relapse prevention benefit from combined use of risperidone60. Currently, three SGA are 
Food & Drugs Administration approved as adjunct (i.e. aripiprazole and quetiapine) or in combination 
(olanzapine-fluoxetine combination) with antidepressant therapy144-146. An analysis of three RCTs 
revealed a statistically significant benefit of risperidone augmentation over placebo, in response rate 
and remission rate, despite a trend towards increased withdrawal due to adverse events with the use 
of risperidone147. Data from open-label studies on effectiveness of ziprasidone as augmenting agent 
antidepressant treatment may be confirmed by findings of recent randomized, double-blind, placebo-
controlled trial149, that have demonstrated the superiority versus placebo of adjunctive ziprasidone in 
escitalopram-treated patients with major depressive disorder.   
 Dopamine agonists- Various dopaminergic agents, including bromocriptine, pergolide and ropinirole 
have been used to augment the efficacy of antidepressant60. Among these agents, the drug, which may 
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offer more advantages is pramipexole. It is a dopamine receptor agonist, with greater affinity for the 
D3 receptor subtype than for the D2 or D4 receptor subtypes. Since D3 receptors are widely distributed 
in the mesolimbic system, activation of these receptors has been supposed beneficial for treating 
depression. Preclinical and early clinical data149,150 suggested that pramipexole may have 
antidepressant effects. The use in augmentation strategy was found to be relatively safe and 
presumably effective in the long-term course of treatment resistant depression151. Recently, a small 
8-week trial152 demonstrated a modest antidepressant augmentation benefit with flexible-dose 
adjunctive of pramipexole in TRD, while a second randomized pilot study proved that combination 
with SSRI was not be more effective than either agent alone in patients with refractoriness to 
antidepressant therapy153. Such data suggest the need for further investigations on dopaminergic 
agonists augmentation of antidepressant treatment.  
Psychostimulants- Psychostimulants are agents known to promote wakefulness, reduce fatigue and 
improve mood; they act by increasing synaptic dopamine, norepinephrine and serotonin to varying 
degrees. As such, the psychostimulants seem a rational candidate as a strategy to improve depressive 
symptoms. The use for this purpose of classical psychostimulants, as methylphenidate, has been a 
long supported by clinical experience and open-label trial or case series154. Recent controlled 
studies155 have reported not statistically significant difference between augmentation with 
methylphenidate and with placebo, in increasing the likelihood of response among patients with 
difficult to treat depression.    
Modafinil is a wakefulness-promoting agent, thought to act primarily on dopamine and 
norepinephrine neurotransmission with secondary elevations of serotonin, glutamate and histamine, 
as well as effects on orexinergic transmission. Although the pooled data from the two placebo-
controlled studies156,157 indicate modest efficacy, it should be kept in mind that these studies were of 
so-called ‘enriched’ samples (i.e. all patients had fatigue and sleepiness) and there is essentially no 
evidence that this augmentation strategy is efficacious for antidepressant non-responders who do not 
have these complaints154. 
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Other agents - Buspirone is an anxiolytic medication that is a partial agonist at 5-HT1A receptors. 
The rationale for studying its efficacy as an augmenting agent was its potential to increase serotonin 
neurotransmission in a way that might enhance the effects of SSRIs and SNRIs, though the 
mechanism of action remains still unknown. While a number of open-label trials159 have suggested 
benefit of buspirone augmentation, two randomized, placebo-controlled, trials159,160 have failed to 
find a significant advantage. 
Pindolol is a β-blocker with presynaptic 5-HT1A antagonist activity, which has shown efficacy as 
augmenting agents in depression treatment. However, a series of small controlled trials161 of its 
prescription in augmentation therapy of well-defined TRD have been negative.  
Anticonvulsants, especially lamotrigine, have been used as augmentation agents, in both treatment-
resistant unipolar and bipolar depression. A systematic review of controlled studies on augmentation 
with lamotrigine for the treatment of TRD patients found that lamotrigine was significantly superior 
to placebo on the Clinical Global Impression Scale for severity and improvement, whilst there was 
not statistically significant difference on the Hamilton Rating Scale for Depression and the 
Montgomery–Asberg Depression Rating Scale162.   
 
 
1.6.2 Physical treatments 
 
Various physical therapies of neurostimulation have documented efficacy in treatment 
resistant depression (TRD) and may be taken into consideration, when adequate antidepressant 
pharmacological treatment fails to induce response.  
Electroconvulsive therapy (ECT) is one of the most effective treatment for refractory depression, with 
a response rate of 50% to 75% among non-responders to antidepressant medication163-165.  
In contemporary clinical practice, ECT can be conducted with minimal risks and side effects. The 
administration by anaesthesiologist of general anaesthesia and pharmacological muscle relaxation 
prevent tonic-clonic muscle activity, while ventilation with oxygen prevents cerebral hypoxia and 
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cerebral electrical stimulation with intermittent square-wave pulses reduces the quantity of energy 
required for provoking a grand mal seizure166. The main clinical drawback is the high rate of early 
recurrence after an initially successful course of ECT: up to 80% within six months167. Rate of 
recurrence may be significantly lowered by maintenance therapy with antidepressant medication.  
In Magnetic Seizure Therapy (MST), seizures are induced with magnetic pulses. The clinical 
procedure (general anesthesia, 9–12 sessions) is similar to ECT. The aim of the development of MST 
was to minimize cognitive side effects through a more focal induction of seizures168. Data from small 
sample sizes open-label studies have reported level of efficacy, similar to ECT, but possibly with a 
superior side-effect profile regarding cognition169. 
Vagus nerve stimulation (VNS) currently represents an effective augmentative therapeutic 
intervention for treatment-resistant depression, as approved by the Food and Drug Administration 
(FDA) in 2005 and by the European Medicines Agency (EMA) in 2001. VNS efficacy in TRD have 
been demonstrated by several controlled and open studies and by a recent meta-analysis comparing 
VNS alone versus VNS plus treatment as usual170. Data from few follow up studies may also suggest 
that VNS can produce a persistent and long-term benefit in terms of acute depressive recovery and 
subsequent prevention of recurrence171,172. 
Repetitive transcranial magnetic stimulation (rTMS) has emerged as a valid treatment for MDD with 
significant efficacy in TRD patients, as proved by a wide range of controlled evidences. In a meta-
analysis of 29 sham controlled randomized controlled trials (RCTs), the overall response rate was 
29.3% with rTMS and 10.4% with sham stimulation173. 
Deep brain stimulation (DBS) is the most invasive neuromodulation technique because it involves 
the stereotactic implantation of unilateral or bilateral electrodes in the brain, connected to a 
permanently implanted, battery-powered neurostimulator174. Despite the relevant and persistent 
antidepressant effect described in small pilot studies175,176, DBS is only available for a highly selected 






1.6.3 Novel treatments 
 
The research on antidepressant therapy for treatment resistant depression (TRD) is to be 
considered a crucial challenge, for both the future of psychiatric clinic and public health. Following 
the discovery of monoaminergic antidepressants (which typically modulate the transmission of 
serotonin and /or norepinephrine in the brain) in the mid-twentieth century, research focused on 
targeting this neurotransmitter system. However, for depressed patients with treatment resistance, 
such treatments simply did not work enough. Innovation began to move away from the monoamines 
and point to the realm of non-monoaminergic augmentation agents, such as lithium and thyroid 
hormone. Despite relative advances made with these medications, many patients still continue to have 
debilitating disease. Thus, the antidepressant research has changed trajectories, focusing on the 
glutamatergic, cholinergic and opioid systems.  
Glutamatergic agents 
Ketamine – In several randomized, double-blind, placebo controlled trials177, 178 ketamine was found 
to have rapid (within 110 min), robust (across a variety of symptoms) and relatively sustained 
(approximately 7 days) antidepressant efficacy at sub anaesthetic intravenous doses (typically 0.5 
mg/kg over 40 min) in well characterized patients with TRD. The efficacy of ketamine has been 
demonstrated in the typically difficult-to-treat subtype of patients with unipolar179 and bipolar anxious 
depression180. Moreover, it has also been shown to rapidly decrease two particularly tough 
symptomatic dimensions as suicidal ideation181 and anhedonia182. Data from literature183 have also 
outlined a favourable safety and tolerability profile for ketamine use in depressed patients, with low 
risk of psychotomimetic effects and increased substance use. Ketamine is classified as a non-
competitive N-methyl-D-aspartate (NMDA) receptor antagonist, though its antidepressant mechanism 
remains still unspecified. Modulation of synaptogenesis has been supposed to play a role184.  
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Lanicemine – Lanicemine is a moderate-affinity low trapping NMDA receptor blocker, which has 
been tested as antidepressant agent in both preclinical and clinical settings, with promising results185 
Memantine – Memantine is a low to moderate affinity NMDA receptor antagonist already approved 
for Alzheimer’s dementia. In last years it has been studied in treatment of different psychiatric 
disorders, depression included. After previous promising findings of open-label pilot studies, more 
recent controlled trials have been largely negative186,187. 
Riluzole – Riluzole inhibits glutamate release via sodium channel inactivation, while blocking 
NMDA-receptor activation and enhancing AMPA expression. It has already FDA approved for 
amyotrophic lateral sclerosis. Data from a small open-labeled study have showed the efficacy of 
riluzole monotherapy for TRD188. Recently research on this drug has turned to its use as augmentation 
of ketamine antidepressant treatment184. 
Anticholinergic agents 
Scopolamine - The rationale of using cholinergic antagonist as scopolamine in antidepressant 
treatment is related to the hypercholinergic state189, which is supposed to be involved in some cases 
of depression. There are evidences of rapidly (within three days) and robustly antidepressant effects 
of scopolamine in both unipolar and bipolar patients with treatment-resistant depression190. 
Scopolamine is a competitive muscarinic M1 receptor antagonist, further two nicotinic receptor agents 
such as mecamylamine and dexmecamylamine have been tested in treatment of TRD, with 
unsatisfactory results191.  
Opioid system agents 
The opioid system is becoming further field of study for potential therapeutic targets. The goal of 
researchers is finding an effective antidepressant compound, without addiction potential. One such 
compound – ALKS 5461 –  synthetized combining buprenorphine (a µ-opioid receptor partial agonist 
and kappa-opioid receptor antagonist) with samidorphan (a µ-opioid receptor antagonist), is ongoing 
studied as antidepressant medication. First recently published data seem to be encouraging in terms 
of both efficacy and safety 192. 
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Monoaminergic agents 
Vortioxetine – Vortioxetine is the most recent drug approved by FDA and EMA for the treatment of 
major depressive disorder. Its antidepressant mechanism of action is supposed to combine direct 
serotonin receptor modulation with serotonin transporter inhibition193. Several clinical studies have 
demonstrated superior antidepressant effect of vortioxetine compared to placebo194. Only one 
randomized, controlled trial has to date tested vortioxetine in patients with previous inadequate 
response to SSRI/SNRI monotherapy195. In this study switching to vortioxetine demonstrated 
superior response and remission rates than switching to agomelatine, with a lower rate of 
discontinuation due to adverse effect. Furthermore, on the basis of findings from systematic review 
of the evidence on clinical cost and effectiveness, the National Institute for Health and Care 
Excellence (NICE) have recently recommended vortioxetine as an option for treating major 
depressive episode in adults whose condition has responded inadequately to two antidepressants 
within the current episode196. 
Complementary alternative medicine (CAM)/Nutraceuticals 
L-methylfolate and S-adenosyl-methionine (SAMe) – Because of their role in neurotransmitter 
synthesis, as well as anti-inflammatory properties, L-methylfolate and SAMe have been studied as 
augmentation agents to antidepressants. A randomized, double-blind trial197on patients with major 
depression, unresponsive to previous SSRI treatment, evaluated the efficacy of L-methylfolate as 
augmenting agent in comparison to combination with placebo. The study was divided in two 30-days 
phases; in the first step L-methylfolate (7.5 mg) did not offer significant improvement in treatment 
outcome compared to placebo. In the second phase, the subjects, whose dose was increased to 15 mg, 
exhibited a significantly greater response rate when compared to individuals receiving placebo. 
Likewise, SAMe (800-1600 mg /day) has showed efficacy as augmentation agents to SSRI. 
Specifically, patients, with insufficient response to SSRI, had significantly greater response and 
remission rates with SAMe augmentation compared with placebo198. 
34 
Anti-inflammatory-immune based treatments 
Infliximab and celecoxib – The cytokine hypothesis of depression provides the rationale for targeting 
the immune inflammatory system in MDD. The monoclonal antibody infliximab was used by 
intravenous administration in outpatients with TRD199. Three infusions of infliximab improved 
depressive symptoms especially in patients with elevated biomarkers of inflammation (i.e. C-reactive 
protein). Both open-label and controlled studies200 suggest that celecoxib and some non-steroidal anti-
inflammatory agents (NSAIDs) are capable of mitigating depressive symptoms when adjunctively 





1.7 Long term outcome in treatment-resistant depression 
 
The natural history of treatment resistant depression (TRD) is generally ominous, marked by high 
rate of recurrence, significant tendency to chronicity, considerable level of functional impairment and 
serious risk of mortality. However, the considerations about severity of clinical course in TRD are 
mainly gathered by clinical practices and expert opinion, because few studies up to date have 
specifically investigated the long term clinical course of depression, after the failure of multiple 
antidepressant trials. A systematic review of available outcome studies of TRD was conducted in 
200910. Collected data demonstrated that TRD is highly recurrence condition, since up to 80% of 
patients, followed up after successful treatment response, were found to relapse within a year8, while 
the remission rate was reported to reduce under the 20% within 2 years201.  Some of these reviewed 
studies have looked at clinical predictors of outcome, founding that good prognosis was predicted by 
initial responsiveness to lithium, absence of previous history of admission, shorter duration of illness 
at intake, less symptoms severity during follow up, while prior history of treatment with lithium and 
presence of delusions and agitation were associated with poorer prognosis6, 202, 203. The only two 
studies, that have investigated social outcome, reported the association of TRD with significant social 
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impairment, both in the short-term and in longer term201,204. The generalizability of these findings is 
limited by the heterogeneity of the surveys included in analysis, many of them were not primarily 
aimed at assessing the longer term outcome of TRD. Recently, Vergunst et al.205sought to describe 
the symptomatic course of illness in a cohort of patients with treatment-resistant unipolar and bipolar 
depression, followed up for a mean of three years. The findings of the study highlighted the poor and 
often unremitting outcome of TRD, since followed-up patients experienced depressive 
symptomatology during the nearly 60% of follow-up period, with a large proportion of this time spent 
in full syndromic depressive episode. Study data may also describe a dynamic and fluctuating course 
of TRD, with patients spending time at multiple symptom severity levels during follow up. The grade 
of symptom severity fluctuation was found to correlate with patients’ level social support and 
diagnosis of illness: lower levels of social support and a diagnosis of bipolar depression were 
associated with a high number of symptom severity level fluctuations per year. If the course of illness 
is marked by the long persistence of the symptomatology for a great proportion of patients of TRD, 
there are also many patients, who can achieve sustained remission. In a prospective study on patients 
with TRD234, followed up for a mean of 3 years after discharging by a tertiary unit, the 60% of 
participants was found to achieve the remission, defined as maintaining asymptomatic or nearly 
asymptomatic state for a minimum of 1 month, and/or the recovery, defined as persistent remission 
for at least 6 consecutive months at any stage of follow-up. Three main factors were identified as 
predictive of the good outcome during follow up: lower severity of treatment-resistant depression 
(measured with the Maudsley Staging Method), greater educational achievement and higher level of 
social support. In current literature it is emphasized the role of multidisciplinary and multimodal 
approach in therapy of depressed patients, with history of failed treatments. Recently, Wooderson et 
al. 206 have demonstrated the long term benefit of individualised, intensive, multidisciplinary inpatient 
treatment in patients with TRD, followed up during median period of 34 months. They found that 





1.8 Treatment resistance in bipolar depression 
 
Bipolar depression accounts for the largest part of morbidity and mortality of bipolar disorder207. 
Depressive episodes occupy the most of the time spent as ill by the bipolar patients207-209 and are 
strongly associated with functional impairment and excess mortality associated with suicide210-212. 
The impact of depression on morbidity of bipolar disorder is made further burdensome by the poor 
efficacy of available pharmacological treatments for acute depressive episode. Quetiapine 
monotherapy is currently the only treatment for bipolar depression, which has been approved by both 
the Food and Drug Administration (FDA) and the European Agency Medicines (EMEA). The Bolder 
studies213,214 Group I and II evaluated the efficacy of 600 and 300 mg/die of quetiapine versus placebo 
in the treatment of bipolar I and II depression, founding that the rate of response and remission was 
significantly higher in the quetiapine groups versus placebo (58% vs. 36%, and 53% vs. 28% 
respectively). There is evidence of efficacy also for the use of olanzapine in combination with 
fluoxetine, that allowed the FDA, but not the EMEA, to approve variable fixed dose olanzapine-
fluoxetine combinations (OFCs) for the treatment of acute bipolar I depression215. No other 
pharmacological treatment has received the approval for the use in bipolar depression. Lithium has 
often been considered the gold standard for the treatment of all phases of bipolar disorder and has 
been traditionally associated with rapid antidepressant effects, mostly in resistant depression studies. 
However, no statistically significant differences in MADRS scores were found between lithium and 
placebo after 8 weeks of treatment, at 0.6 mEq/l mean lithium serum levels in the acute phase of 
bipolar depression in the EMBOLDEN I study216. Among anticonvulsants, controversial data have 
been collected on the use of lamotrigine. After some evidence of efficacy from early studies, recent 
reviews of RCTs did not demonstrate statistically significant difference between lamotrigine 
monotherapy and placebo in the treatment of acute bipolar depression217,218. Despite the controversy 
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surrounding their use, antidepressants still remain commonly prescribed to bipolar depressed patient. 
In addition to the widely known association with the induction of mania or rapid cycling, the more 
recent evidence may confirm that antidepressants are less effective for treating bipolar depression 
than major depressive disorder219.  
Thus, the remarkably high proportion of unresolved long-term depressive morbidity in bipolar 
disorders suggests that treatment-resistance represents a major clinical challenge also for these 
illnesses. Nevertheless, the concept of resistance in bipolar depression is far from a theoretical and 
operational definition. The first attempt to define the refractory bipolar depression was based on the 
concept of failed remission despite two adequate trials of standard classes of antidepressant agents 
(at least 6 weeks each and adequately dosed), with or without augmentation220. Successive proposals 
relied instead on the criteria of failed respond to particular treatments, such as a trial with lithium at 
serum levels of 0.8 mmol/l221. In the context of a systematic definition of treatment-resistant bipolar 
disorder, Gitlin222 suggested to apply to bipolar depression the same criteria used for treatment-
resistant unipolar depression, with the condition that failure to respond to mood stabilizers as well as 
antidepressants, should be added to the definition. Such conceptualization of treatment resistance in 
bipolar depression has been discussed by some authors, because it may not take into consideration 
the substantial differences between bipolar and unipolar depression, in terms of dimensional, 
phenomenological and clinical features. There is in fact evidence showing that bipolar depression is 
characterized more frequent than unipolar by atypical depressive symptoms as hypersomnia, 
hyperphagia, leaden paralysis and psychotic phenomena, furthermore clinical course of patients with 
bipolar depression is marked by an earlier age of onset, shorter duration of episodes, higher number 
of past depressive episodes, and family history of bipolar disorder223. Regarding the response to 
antidepressant treatment, the distinct traits of bipolar depressed patients from unipolar ones may 
consist in higher rates of short-term non-response, manic switch, cycle acceleration and new rapid 
cycling, tolerance to therapeutic effect of drugs and depressive relapse after discontinuation111. In line 
with these observations, Pacchiarotti et al.224 have proposed an alternative definition of treatment 
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resistance in bipolar depression, based on the criteria of the failure to achieve remission with 
adequately dosed lithium (0.8 mEq/L in the plasma) or with other adequate ongoing mood-stabilizing 
treatment, plus lamotrigine (50-200 mg/day) or with a quetiapine monotherapy at full dosage (600 
mg/day), for bipolar I patients, or at a dose range of 300-600 mg/day for bipolar II.   
The studies that have examined the next step treatment strategies for resistant bipolar depression still 
remain few. No clear guidelines exist concerning what to do when the first approved therapies failed. 
Recently, Tondo et al.225 reviewed the current evidence on the various pharmacological agent tested 
in literature for treatment-resistant bipolar depression. They reported that controlled evidence of 
efficacy was available only for ketamine226,227, although it is short-acting and not orally-active, and 
weakly for pramipexole149, while data from uncontrolled trials228-231 suggested a potential utility for 
























2. Aim of Study 
 
In the present study we examined a sample of depressed inpatients during a one-year naturalistic 
follow-up. The aims of the study were:  
✓ to investigate the socio-demographic and clinical characteristics associated with treatment 
resistant depression (TRD) 
✓ to prospectively evaluate the course and the outcome of TRD over a one-year naturalistic 
follow-up   
✓ to compare clinical and therapeutic characteristics of sub-groups of patients, distinguished on 
the basis of the outcome:  
o Remitters (patients with remission during 1-year follow up) versus Non-remitters 
(patients without remission and patients with relapse during 1-year follow up) 
o  Relapsed (patients with relapse after remission during the follow-up period) versus 













The study was a retrospective follow-up of patients with treatment resistant depression, recruited 
during hospitalization in a specialist tertiary unit. Follow up data were collected using both cross-
sectional and longitudinal assessment. 
 
3.2 Study population 
 
A consecutive series of 50 patients were recruited from January 2008 to January 2009 in 
Depression Treatment Resistance Centre in Psychiatric Clinic of Pisa (Italy), a specialist inpatient 
centre, which accepts patients referred from across Italy. Multimodal treatment incorporating the 
major evidence-based therapies for affective disorders is offered, including pharmacotherapy 
(typically drugs combinations and high dose therapy, where indicated) and physical therapies (ECT) 
as indicated. All patients were referred with a depressive episode, which was considered resistant to 
treatment. Diagnosis was established using the Diagnostic and Statistical Manual for Mental Disorder 
(DSM), 4th edition revisited, after a full, longitudinal clinical assessment including patient history, 
old case notes and the use of appropriate standardised interviews as Structured Clinical Interview for 
DSM (SCID), Montgomery-Asberg Depression Scale (MADRS), Mania Rating Scale (MRS). Only 
patients with a primary diagnosis of Major Depressive Disorder (MDD) or Bipolar Disorder (BD) 
were included in the study. Treatment resistance was graded on the basis of Thase and Rush staging 
method.  
Inclusion criteria: 
✓ diagnosis of MDD or BD 
✓ failure to achieve remission after at least one antidepressant trial of one major class of 
antidepressant at adequate dose (equal to or higher than the lowest dose defined as effective 
41 
in the product datasheet) and an adequate duration at least 4 weeks  
✓ current Depressive Major Episode  
✓ baseline Montgomery-Asberg Depression Scale (MADRS) score ≥ 21.  
Exclusion criteria: 
✓ patients with a mood disorder secondary to any primary “non-affective” psychiatric condition,  
✓ patients unable to understand or provide written informed consent  
✓ age< 18 years  
✓ acute somatic illness (kidney and liver failure, presence of a serious heart condition, epilepsy 
or conditions predisposing to epilepsy, other neurological diseases, pregnancy, substance 
abuse over the previous six months or drug dependence)  




Axis I diagnosis was established using DSM-IV-TR criteria by means of Structured Clinical 
Interviews (SCID-IV). Montgomery-Asberg Depression Scale (MADRS), Mania Rating Scale 
(MRS), Clinical Global Impression Scale (CGI), Global Assessment of Functioning (GAF) were used 
to establish symptom severity and level of functioning. Number of weeks of remission, relapses, 
hospitalizations, suicide attempts, and pharmacological therapies have been evaluated using clinical 
records.  
Patients were evaluated using MADRS, MRS, CGI, GAF at enrolment and after 4, 8, 16, 32, 48 
weeks, in order to examine the prospective course of the disorder.  





3.4 Outcome definition 
 
The main outcomes of interest were response, remission, recovery, relapse and recurrence. 
 Response: reduction of the initial score of the MADRS scale ≥ 50%  
 Remission: temporary abatement (at least 8 weeks) of symptom: the individual no longer 
meets syndromic criteria for the disorder (MADRS score≤12, HAM-D score<7)  
 Recovery: it implies a more sustained remission (at least 6 months) and raises the possibility 
that treatment can be discontinued or prolonged with the aim of prevention. 
 Relapse: the return of a disease after its apparent cessation (during the period of remission) 
 Recurrence: the return of symptoms after recovery (after 6 months) 
 
 
3.5 Instruments  
 
Clinical Global Impression 
 CGI is structured in 3 items. Item 1 of the Clinical Global Impression that assesses the severity of 
the disease by dividing it into 7 points (0 = has not been assessed, 1 = normal (absence of mental 
illness), 2=only marginally ill 3 = mildly ill, 4 = moderately ill, 5 = greatly ill, 6 = severely ill, 7 = is 
among the sickest patients)  and the item 2 that assesses the improvement from baseline (0= has not 
been assessed, 1= much improved, 2= moderately improved, 3= slightly improved, 4= no change, 5= 
slightly worse, 6= moderately worse, 7= much worse). 
Item 3 assesses the effectiveness of treatment and side effects. 
Montgomery-Asberg Depression Rating Scale (MADRS) 
MADRS is composed of 10 items that explore the mood, feelings of discomfort (internal stress), 
sleep, appetite, concentration ability, initiative, emotional involvement, pessimism and the desire to 
live. Each item is rated on a 7-point scale (0 = absence of symptom; 7= very serious), the total score 
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is calculated by the sum of the responses to the 10 items and must be between 0 and 27 (higher scores 
indicate a greater impairment). 
Young Mania Rating Scale 
This test is one of the most important rating measures for evaluating mania symptoms232. This scale 
has 11 items, which is completed based on the patients’ subjective report by regarding their clinical 
status over the past 48 h. These 11 items are increased mood, increased energy and locomotor activity, 
sexual desire status, sleeping, excitability, rate and amount of speech, language, and thought disorder, 
thought content, destructive and aggressive behaviour, appearance, and attitude. Scale for rating 
severity of each item was determined from 0 to 4 and in some cases 0–8 points.  
Structured Clinical Interview for DSM-IV-Axis I Disorders/Patient edition (SCID-I/P) 
SCID-I/P is a semi-structured clinical interview developed by Spitzer and colleagues (1992) to 
diagnose Axis I disorders according to DSM-III and then updated according to DSM-IV criteria. It is 
composed of 9 modules containing all the questions to investigate the existence of criteria for different 
diagnostic categories (mood disorders, anxiety disorders, substance abuse, eating disorders, etc.), as 
well as providing an assessment of gravity. Each module is independent and can be used separately 
from the other according to specific searches. The interview follows hierarchical rules that, if the 
presence of a disorder excludes another, the latter is not under investigation. One to two hours are 
required to complete the interview, depending on the complexity of subject's psychiatric history and 
his/her ability to clearly describe current symptoms or history. 
Global Assessment of Functioning GAF 
This scale was administered to obtain a clinician rated judgment about the patient's current level of 
psychological, social and occupational functioning233. The scale values range from 1 to100 on a 
hypothetical continuum of mental health to mental illness. A score higher than 70 indicates no more 
than slight impairment in social or occupational functioning. 
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3.6 Statistical analyses  
 
Descriptive analyses were reported in terms of mean and standard deviations for continuous 
variable and number and percentages for categorical ones.  Pairs-sample T Test was employed to 
compare baseline vs endpoint scores of scale measuring symptom severity and level of functioning.  
In spite of the small sample size, comparisons between Remitters and non-remitters and 
Relapse and Non-Relapse were conducted in order to explore possible features associated with 
treatment resistant depression remission and relapse. Comparisons for categorical variables were 
conducted by using χ2 tests and comparisons for continuous variables were performed with the 
independent-sample Student’s t-test. The major limitation of the present study is the low number of 
subjects classified as Remitters and Relapsed. Since the high possibility of both type-I and type-II 
error, our results should be considered preliminary. At this stage we commented the significant 
differences at a p<.05 level. However, given the exploratory nature of our study, we also commented 
p<.10 difference in order to minimize type I error.   















4.1. Socio-demographic and clinical characteristics of the sample 
 
Fifty patients, hospitalized in our centre with the diagnosis of major depressive episode, 
unresponsive to at least one adequate antidepressant trial, were recruited in the study. Socio-
demographic and clinical features of sample are summarized on tables I and II.  
Female patients were the majority of the sample (n=40, 75%); 38 (76%) study participants were 
married, 8 (16%) were single, 8 (4%) divorced or widower. The majority of sample was unemployed 
(n=32, 64%), while only one third of patients (n=18, 36%) was employed. Education level was 
medium/high in 31 (62%) patients, medium/low in the remaining 19 (38%). Mean age of sample was 
53.46 years (sd=11.80), while mean age at onset of illness was 31.26 years (sd=14.12). The most 
common diagnosis in the cohort was Bipolar Disorder type I (n=20, 40%), Bipolar Disorder type II 
was diagnosed in 12 (24%) subjects, while 18 (36%) patients showed a diagnosis of Major Depressive 
Disorder. First degree family history of mood disorder was reported in 32 (64%) subjects of the 
sample. In all patients, illness began with a depressive episode (n=50, 100%), and the course was 
highly recurrent, with 3.54 (sd=2.43) depressive episode on average, 0.70 (sd=1.50) (ipo)manic 
episode, 0.44 (sd=0.86) manic episode, 0.46 (sd=0.78) mixed episode. The relative severity of illness 
was suggested also by the high mean number of hospitalizations (2.84; sd=2.11), the significant 
percentage of suicide attempts (n=11; 22%), the high frequency of family history for both mood 
disorder (n=32; 64%) and suicide (n=6; 12%). Most of the study population showed at least one 
mental disorder in comorbidity (n=34; 68%). Psychiatric comorbidity was represented mostly by an 
anxiety disorder (n=30; 60%), while comorbidity with Obsessive-Compulsive Disorder and 
Substance Use Disorders was diagnosed respectively in 4 (8%) and 5 (10%) patients.  
Comorbidity with a medical illness has been found in 28 patients (56%), and it was represented 
mainly by comorbidity with a cardiovascular disease (n=17; 34%). Mellitus diabetes and thyroid 
diseases were instead reported in 4 (8%) and 7 (14%) subjects of the sample respectively. Further 13 
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(26%) patients showed other physical illness. Concerning clinical characteristics of current major 
depressive episode, 31 (62%) patients showed a melancholic symptomatology, while psychotic 
symptoms were found in 5 (10%) subjects. In the remaining fourteen (28%) patients, depressive 
symptomatology showed atypical features.  
 
4.2. Clinical course and treatment of sample during follow up 
Baseline symptom severity was on average high, as indicated by mean scoring on MADRS 
(33.3; sd=6.7) and CGI Severity (4.76; sd=1.02). Baseline mean score on GAF was 49.28 (sd=7.44) 
suggesting a moderate functional impairment. During 1-year follow up, MADRS and CGI severity 
score dropped to achieve endpoint average of 20 (sd=11.29) and 3.8 (sd=1.19) respectively, while 
GAF mean score increased from 49.28 to 61.22. Baseline and Endpoint mean scores of MADRS, 
CGI severity and GAF resulted significantly different with a relevant mean reduction (MADRS: -
13.36, sd=12.44, p=0.00; CGI I° item: -0.960, sd=1.5, p=0.00; GAF: +12.6, sd=14.9, p=0.00). These 
findings, added to endpoint mean score at item Improvement on CGI (2.94; sd=1.55) may indicate 
that patients’ clinical status tend to improve, regardless treatment. Patients’ therapeutic regimen was 
characterized mainly by multi-drugs approach. At baseline 17 (34%) patients assumed augmentation 
therapy, 13 (26%) followed an antidepressant combination, the remaining 20 (40%) was treated with 
antidepressant monotherapy. Mean grade of resistance to treatment, according to Thase and Rush 
staging method, was 1.88 (sd=0.87). During 1-year follow up the use of combined treatments tend to 
increase, since 19 (40.4%) patients assumed augmentation therapies, the same number was found to 
be treated with antidepressant combination, only 6 (12.6%) subjects assumed monotherapy 
antidepressant (see table V and graphics 3 and 4).  
Concerning the pharmacological class, SSRI/SNRIs and TCAs were the most common drugs 
prescribed in the sample, both at the baseline, when 30 (60%) patients assumed SSRI/SNRIs and 33 
(66%) assumed TCAs, and at the end of follow up, when patients assuming SSRI/SNRIs and those 
treated with TCA were the same number (68%; n=34). During period of observation, the use of 
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lithium in the sample tend to increase: from 16 (32%) patients at baseline to 24 subjects (48%) at the 
endpoint, such as the administration of SGA: from 11 (22%) to 14 (28%) patients. The number of 
patients assuming BZD reduced during follow up, falling from 36 (72%) to 24 (48%). 
 
4.3. Comparison of socio-demographic and clinical characteristics between patients 
with (remitters) and without remission (non-remitters) 
 
During 1-year follow up, 20 (40%) patients achieved the clinical remission (remitters), 
defined by MADRS score ≤ 10 for at least 8 weeks, while the remaining 30 patients failed to achieve 
remission (non-remitters). The comparison of socio-demographic and clinical variables between 
remitters and non-remitters is summarized in Table I and II.  
Only one male achieved remission (5%), while 19 of 20 (95%) remitters were female. Among non-
remitters females were 21 (70%), while males 9 (30%). The difference for the frequency of females 
between the two groups resulted statistically significant (p=0.03). No other socio-demographic 
variable resulted significantly different between the two groups. Mean age at onset of illness was 
considerably, although not statistically, higher among remitters than in the group of non-remitters (36 
vs 28.7; p=0.09). There were no relevant differences between the two groups in terms of percentage 
of patients with first degree of family history for mood disorder (65% n=13 remitters vs 63.3% n=19 
non remitted; p=0.90) and for suicide (15% n=3 remitters vs 10% n=3 non-remitters). Rate of suicide 
attempts was not statistically different among remitters and non-remitters (25%, n=5 vs 20%, n=6; 
p=0.67), as well as the mean number of hospitalizations (2.90, sd=1.72 vs 2.75, sd=2.63; p=0.80). 
Concerning the diagnostic profile of the two groups (see graphic 1), Major Depressive Disorder and 
Bipolar Disorder type II were diagnosed more frequently among remitters (40% n=8 vs 33.3%, n=10; 
- 30% n=6 vs 20%, n=6), while non-remitters presented more commonly diagnosis of Bipolar 
Disorder type I (46.7%, n=14 vs 30%, n=6). However, none of these differences achieved statistical 
significance. Remitters and Non-remitters did not show significant differences in rate of comorbid 
Anxiety Disorders (66.7%, n=20 vs 50%, n=10; p=0.23), Obsessive Compulsive Disorder (10%, n=3 
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vs 5%, n=1; p=0.52), and Substance Use Disorder (15%, n=3 vs 6.7%, n=2; p=0.33). The comparison 
of physical illness comorbidity between the two groups revealed similar rates of cardiovascular 
disease (40%, n=12 vs 25%, n=5; p=0.27), diabetes (10%, n=2 vs 6.7%, n=2; p=0.67) and thyroid 
diseases (20%, n=4 vs 10%, n=3; p=0.31).  
Concerning previous clinical course, the difference between the two groups consisted in the higher 
mean number of manic episode on average in the group of non-remitters (0.47, sd=0.90 vs 0.40, 
sd=0.82; p=0.79) and in the greater mean number of depressive (4.25, sd=3.19 vs 3.07, sd=1.66; 
p=0.09) and of (ipo)manic episode among remitters (1.20, sd=2.16 vs 0.37, sd=0.66; p=0.05). Higher 
recurrence of (ipo)manic episode in the group of remitters, compared to non-remitters, was 
statistically significant and may indicate, with data on previous depressive and manic episode, that 
the clinical course of remitters was characterized by more evident cyclicity, compared to non-
remitters. 
 
4.4. Comparison of clinical course and treatment between remitters and non-remitters 
during 1-year follow up. 
 
Depressive specifier of current episode was not significantly different between remitters and 
non-remitters, percentages of melancholic features (65%, n=13 vs 60%, n=18; p=0.44), psychotic 
symptoms (15%, n=3 vs 10%, n=3; p=0.44) and atypical features (33.3%, n=10 vs 20%, n=4; p=0.44) 
were similar. Mean duration of depressive episode was longer in the group of non-remitters (8.93 
weeks, sd=6.97 vs 6.75 weeks, sd=5.11), but the difference was not statistically significant. The two 
groups did not differ from each other for the baseline symptom severity, as shown by comparing 
MADRS scores (non-remitters 34.03, sd=6.50 vs remitters 32.35, sd=7.05, p=0.39) and CGI item 
Severity scores (non-remitters 2.23, sd=2.11 vs remitters 2.00, sd=2.36; p=0.71). During 1-year 
follow up, the differences of clinical conditions between the two groups became remarkable, in terms 
of more significant improvement of remitters’ clinical status (MADRS endpoint: 9.65 sd=6.31 vs 
26.90 sd=8.15, p=0.00 - CGI Severity endpoint: 3.10 sd=1.29 vs 4.27, sd=0.86; p=0.00 – CGI 
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Improvement endpoint 1.75 sd=0.96 vs 3.73 sd=1.36 - GAF endpoint: 72.54, sd=9.34 vs 54.83, 
sd=10.5; p=0.00) (see graphics 5 and 6).  
Regarding treatment course, there were not significant differences, related to the type of baseline 
therapeutic strategies. Current stage of resistance, according to Thase and Rush method staging, was 
higher in the group of non-remitters, but the difference was not statistically significant (2.03, sd=0.92 
vs 1.65, sd=0.74; p=0.80) (see graphic 2). We reported in table V also the treatment strategies, 
followed by remitters at time of remission: the majority of group assumed augmentation therapies 
(35%, n=7), four (20%) patients were treated with antidepressant combination, only one subject 
assumed a monotherapy. Optimization and switching were found to be used at time of remission in 
the same proportion of remitters (n=2, 10%). The comparison between remitters and non-remitters, 
regarding the assumed pharmacological classes, revealed that at baseline the rate of prescribing for 
each drug class was not significantly different between the two groups. At the endpoint, instead, the 
assumption of SSRI was significantly more frequent among non-remitters (80%, n=24 vs 50%, n=10; 
p=0.02). 
 
4.5. Comparison of socio-demographic and clinical characteristics between patients 
with relapse (relapsed) and without relapse (non-relapsed) 
 
Three patients, who achieved clinical remission, developed the relapse of major depressive 
episode, before ending of follow up. The comparison between this subgroups of patients (relapsed) 
and the subgroups of subjects, who keep remission during follow up (non-relapsed) is summarized 
in Table III and IV.  Relapsed patients were female (100%, n=3), mainly unemployed (66.7%, n=2) 
and having low/medium level of education (100%, n=3). The differences concerning the marital status 
between the two groups resulted statistically significant: none of relapsed patients was 
divorced/widower, while there was neither single among non-relapsed.  
Mean age was higher in relapsed than non-relapsed patients (57.67 sd=4.04 vs 55.53 sd=9.91), 
although the difference was not statistically different. The majority of relapsed patients had Bipolar 
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Disorder type II (66.7%, n=2 vs 23.5%, n=4), while non-relapsed patients were mainly affected by 
Major Depressive Disorder (41.2%, n=7 vs 33.3%, n=1). One relapsed patient had comorbid 
diagnosis of Anxiety Disorder (33.3%), another one showed Substance Use Disorder (33.3%). In the 
subgroups of non-relapsed patients instead 9 (52,9%) subjects had comorbid Anxiety Disorder, two 
(11.8%) presented Substance Use Disorder, only one (5.3%) patient had comorbid Obsessive-
Compulsive Disorder. The co-presence of Cardiovascular Disease was higher in relapsed patients 
than in the group of non-relapsed, although the difference was not statistically significant (66.7%, 
n=2 vs 17.6%, n=3; p=0.07). Previous clinical course of relapsed patients was characterized on 
average by 4 (sd=1.73) depressive episodes and 1.33 (sd=1.52) (ipo)manic episodes. Number of 
hospitalization was similar (4, sd=3.6 vs 2.29, sd=2.59).    
 
4.6. Comparison of clinical course and treatment between relapsed and non-relapsed 
during 1-year follow up. 
 
Relevant, although not statistically significant, differences between the two subgroups 
emerged from the comparison of symptomatologic profile. Atypical features were found in two 
(66.7%) relapsed patients, while melancholic symptoms characterized current depressive episode of 
12 (70.6%) non-relapsed patients versus the only one relapsed ones. There were not cases of psychotic 
depression among relapsed patients (p=0.08). Symptom severity was not significantly different 
between the two groups relapsed, as shown by comparison of baseline MADRS (34, sd=8.18 vs 32.06, 
sd=7.08; p=0.67) and CGI Severity mean scores (1.67, sd=1.52 vs 1.06, sd=2.35; p=0.79). At 
endpoint such differences were obviously more evident: the gap of MADRS mean score was 11 (19, 
sd=3.46 vs 8, sd=5.14; p=0.02) and the difference between CGI Severity mean score 1.16 (4.27, 
sd=0.86 vs 3.10, sd=3.10; p=0.00). Better outcome of clinical course among non-relapsed patient 
versus relapsed ones was shown also by the gap between CGI Improvement endpoint mean score 
(2.33, sd=1.15 vs 1.65, sd=0.93; p=0.26). Concerning therapeutic regimen, the differences between 




4.7 Comparison between Unipolar and Bipolar treatment resistant depression (TRD) 
 
Thirty-two patients (64%) received the diagnosis of Bipolar Disorder I or II and the remaining 
18 (36%) the diagnosis of Major Depressive Disorder. The two subgroups of bipolar and unipolar 
patients were compared for clinical and therapeutic features (table VI and VII). 
Mean age at enrolment and mean age at onset of affective disorder were similar in the two groups, as 
well as the number of previous episodes. Bipolars and unipolars were not significantly different also 
for the rate of psychiatric and physical comorbidity. Clinical history of bipolar patients was 
characterized by significantly higher number of previous hospitalization (3.28, sd=2.51 vs 2.06, 
sd=1.83, p=0.04). Significant differences between the groups emerged also in the symptomatological 
profile of the current episode (see graphic 7). Melancholic specifier resulted statistically more 
frequent among bipolar patients (n=24, 75% vs n=7, 38.9%; p=0.01), while the rate of atypical 
features was higher, although not significantly, in the subgroup of unipolar patients (n=9, 50% vs 
n=5, 15.6%; p=0.09). The subjects with unipolar treatment-resistant depression had considerably, 
although not significantly, longer duration of current episode (11.17 months, sd=7.80 vs 6.31 months, 
sd=4.61; p=0.08). Baseline symptoms severity was similar, as measured by MADRS (33.56, sd=7.28 
vs 33.00, sd=5.74; p=0.78) and CGI 1°item scores (4.81, sd=0.74 vs 4.67, sd=1.41; p=0.63) (see 
graphic 8). During follow up depressive symptomatology of both groups tended on average to 
improve, though at endpoint unipolar patients’ general conditions may appear better than bipolar, as 
suggested by the significantly lower CGI 1°item score (3.33, sd=1.23 vs 4.06, sd=1.08; p=0.03) (see 
graphic 9). The proportion of patients achieving remission during follow up was similar: 12 (37.5%) 
subjects among bipolar and 8 (44.4%) among unipolar. The two groups showed also similar rate of 
relapse. Regarding the pharmacological treatments, the rate of patients assuming antidepressants was 
similar and high in both groups. As expected, the baseline use of lithium resulted significantly more 
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frequent among bipolar patients (n=14, 43.8% vs n=2, 11.1%; p=0.02), though the number of unipolar 
patients assuming lithium increased during follow up, reducing the gap. Interestingly, the assumption 
of benzodiazepines in bipolar was significantly higher than in unipolar at baseline (n=26, 81.2% vs 
n=10, 55.6%; p=0.05). A relevant, although not statistically significant, difference emerged from the 
use at endpoint of SGAs, that resulted higher in bipolar than in unipolar patients (n=13, 41.9% vs 



















We carried out a naturalistic 1-year follow up of fifty patients, affected by both unipolar and 
bipolar depression, unresponsive to at least one adequate antidepressant trial. The sample was 
composed mostly by female, middle aged, unemployed, with medium/high level education and 
married individuals. This socio-demographic profile seems to be in large part consistent with 
epidemiologic data on depression, that indicates the illness as prevalent among female population and 
middle aged subjects, and as more frequent in individuals with medium/high level of schooling than 
ones with low schooling1. The high frequency of unemployed (64%) in the sample may be in line 
with the positive relationship of unemployed status with treatment resistance234, described in some, 
but not all, the studies on socio-demographic variables of antidepressant treatment outcome.  
The analysis of information about previous clinical course reveals for the majority of the sample a 
long and severe history of illness, with relative low mean age of onset, high mean number of previous 
episode, great average of hospitalizations and considerable rate of previous attempts of suicide. The 
clinical features of our patients may be supposed to contribute to the antidepressant therapy 
refractoriness, since illness severity has been identified as one of the most important determinants of 
treatment resistance234. The high prevalence of comorbid psychiatric and/or physical disorders is to 
consider further evidence of patients’ serious clinical conditions. Concerning psychiatric comorbidity, 
the co-existence of an anxiety disorder (excluding obsessive-compulsive disorder) was found in the 
60% of our sample. The two more recent and larger studies27, 70 on clinical determinants of treatment 
resistant depression (TRD) were consistent in identifying comorbidity with anxiety disorders as a 
predictor of treatment resistance. The role of comorbid anxiety on antidepressant treatment outcome 
has given food for thought about debate on the reliability of diagnosis of TRD. Recently, Parker and 
Graham27 have found in a large sample of patients with TRD a strong correlation of the treatment 
resistance with the regular use of benzodiazepines (BZDs). The authors indicated among the possible 
explanations, besides the contributing of anxiety comorbidity to treatment outcome, also the 
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hypothesis that anxiety may be a consequence of the resistant depressive state. Commenting the 
finding of relationship between TRD and use of benzodiazepines, Silbermann and Weiss236 have 
raised the issue of misdiagnosis of anxiety disorder with treatment refractory depression. They 
denoted the growing tendency for psychiatrists to hastily label dysphoric mood, self-injuring thoughts 
or behaviours associated with anxiety disorders, as symptoms of primary affective disorder. 
According the authors, this diagnostic bias may contribute to creating the population of treatment-
resistant patients described in Parkers and Graham’s study, who might have responded to adequate 
courses of BDZs and nonmedical treatments targeted to anxiety. Another possible explanation is that 
the chronic use of benzodiazepine might represent a factor of resistance in itself. Benzodiazepines 
dependence in anxious people have been shown to be related to chronicity of the anxious 
symptomatology and treatment resistance. 
The 56% of our patients presented concomitant physical illness, mainly represented by cardiovascular 
disease. The literature data on the role of physical comorbidity on treatment outcome are not 
conclusive. On the one hand, the co-existence of medical conditions has been indicated as a 
significant contributing factor to the occurrence of TRD in several studies, including a recent 
investigation in primary care centres in Canada237. The authors reported that medical comorbidity 
was an important determinant of TRD and recommended that the treatment of TRD should address 
medical conditions (such as chronic pain and obesity). On the other hand, some studies, such as a 
recent investigation on the data derived from the European multicentre survey238, designed by the 
Group for the Study of Resistant Depression (GRSD) to examine clinical variables of TRD, have 
found no differences between TRD and non-TRD patients in rate of physical comorbidity. This 
apparent discrepancy might be related to differences in study design and population and in tools to 
measure physical comorbidity. In our experience an efficient management of patient with TRD cannot 
exclude an accurate investigation, eventually followed by adequate treatment, of medical conditions, 
that could exacerbate depressive symptoms, interfere with antidepressant medication and impair 
global functioning.  
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The majority of study population (60%) had a Bipolar Depression, while the 40% of patients 
presented Unipolar Depression. The relative risk of TRD in bipolar versus unipolar mood disorders 
has not been evaluated systematically, but it would not be surprising to find it more often in bipolar 
disorders than in unipolar depression. A poor response to several adequate antidepressant treatment 
trials in unipolar depression has also been suggested to be a sign of bipolarity. Data from early 
studies103,106 showed that more than 50% of the people with unipolar treatment-resistant depression 
were subsequently diagnosed with hidden bipolar disorder, when reappraised during the follow-up 
period. Analysing the data from a recent study on the association of treatment-resistance and the 
subsequent diagnosis of bipolar disorder in a cohort of patient with unipolar depression, Tondo et 
al.104,225 have calculated a two-fold greater prevalence of TRD in bipolar disorders (41.7 %) than in 
subjects diagnosed with unipolar major depressive disorder (21.2 %).  
The melancholic type was the most common specifier of current depressive episode in our sample 
(62%). The relationship between treatment outcome and depressive subtype is still debated in 
literature. In the European multicentre study of GRDS the melancholic subtype was more 
significantly prevalent among patients with TRD than ones with no treatment refractory. However, 
the role of symptomatologic profile on treatment outcome may be dependent of the type of treatment. 
For example, there is evidence that atypical depression is associated with poorer response to treatment 
with tricyclic antidepressants (TCAs), but not to selective serotonin reuptake inhibitors (SSRIs)239 or 
monoamine oxidase inhibitors (MAOIs)240, while melancholic depressive syndrome was more 
responsive to TCAs than SSRIs. 
In our sample the mean duration of current depressive episode was moderately long: nearly 8 months; 
this finding was partly consistent with the importance attributed by recent literature to the contribute 
of long duration of current episode to the treatment refractory4.  
According to the literature, symptom severity is another important determinant of TRD 39,66,95. In our 
study population, baseline symptoms severity was on average high, as indicated by mean MADRS 
and CGI Severity score: 33.36 and 4.76, respectively. During the follow up our patients’ clinical status 
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tend then on average to improve: baseline and endpoint mean scores of MADRS and CGI severity 
resulted in fact significantly different with a relevant reduction (MADRS: -13.36, sd=12.44, p=0.00; 
CGI I° item: -0.960, sd=1.5, p=0.00). Overall, the clinical profile of our sample appears to be 
consistent with the existing literature on the clinical characteristics of TRD. The grading of treatment 
resistance was on average moderate; current stage of treatment resistance, according to the Thase and 
Rush staging method, was for the majority of the sample (72%) the stage I or II, corresponding to the 
failed response to one or two adequate antidepressant trials. Our patients assumed in large majority 
multi-drugs therapies, composed mainly by SSRIs (60%) or TCAs (66%). Among the advised 
therapeutic strategies for TRD, the more adopted in our sample were the augmentation of currently 
prescribed antidepressant with a non-antidepressant drug (40%) and the combination of at least two 
antidepressant drugs (40%). 
Regarding the follow up outcome, the first relevant finding of the study was the considerable 
proportion of patients achieving remission. Over the year of follow up, in fact, the 40% of the sample 
(remitters) achieve remission, defined as the maintenance for at least 8 weeks of symptoms levels, 
corresponding to a score ≤ 10 on MADRS scale. Only 15% of the remitters showed subsequently a 
relapse of the depressive symptoms. Thus, the percentage of the whole sample, which kept remission 
at endpoint was 34%.  Few studies have investigated the long-term outcome of patients with TRD 
and have then reported data, with which we can compare our findings. One of these few studies on 
TRD201 looked at the 1- to 2-year outcome of patients with moderately advanced unipolar and bipolar 
treatment-resistant depression in a multicentre study setting. The 1- and 2-year remission rates, 
defined with a self-rated measure, were very low (3.7% and 7.8% respectively). However, the study 
was part of a treatment trial and remission was determined for each visit on the basis of the severity 
of symptoms in the 7 days prior to the visit rather than longitudinally for the whole follow-up 
duration. Another follow-up study244 of 66 patients with TRD (both unipolar and bipolar) investigated 
the outcomes at a mean of 30 months follow up. The 71% of patients resulted as having a good or 
fair outcome. It is to consider that our sample is composed by patients recruited during the 
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hospitalization in a tertiary centre, which is specialized for the multidisciplinary treatment of affective 
disorders. In 2012 Fekadu et al.234 published the findings from a study of the long-term outcome of 
treatment-resistant depression on a sample of 118 TRD patients discharged from a tertiary unit for 
treatment-resistant mood disorders in the United Kingdom. They considered, besides the remission 
defined as the persistence of asymptomatic or nearly asymptomatic state for a minimum of 1month, 
also recovery from an episode, defined by maintaining remission for at least 6 consecutive months at 
any stage of follow-up. Over an average follow up period of 3 years, the 48.3% of the sample achieve 
the recovery, while the 11.9% had met remission criteria without ever achieving recovery. Wooderson 
et al. 206 evaluated the long term symptomatic and functional outcome of 71 TRD patients, after the 
intensive and multidisciplinary treatment in a specialist unit. About half of patients were found to be 
in remission at follow-up (a median of 30 months after discharge), while overall two-thirds were 
judged to have a good clinical outcome. Despite differences in sample size and duration of follow up, 
our findings may be considered comparable to the results of these last two studies and then consistent 
with them in supporting the long-term efficacy of individualized, intensive and multidisciplinary 
inpatient treatment in a relevant proportion of patients with TRD. At the same time, it should not be 
overlocked that the majority of our sample (60%) showed a poor outcome during follow up, since 
they kept experiencing depressive symptoms during 1-year follow up or developed a maniacal or 
mixed switch. This figure confirms the serious and chronic nature of treatment-resistant depression 
and the need to improve current treatments. 
Considering data on pharmacological treatment, at the time of remission, the majority of remitters 
had been treated with multi-drug therapeutic strategy, represented by augmentation treatment in 35% 
and antidepressant combination in 20%. In literature a systematic comparison of efficacy among the 
advised therapeutic strategies for TRD is still lacking. However, the combined therapy (augmentation 
and antidepressant combination) appears to find more favour both in clinical practice than in research.  
The comparison of sociodemographic and clinical variables between remitters and non-remitters 
found two statistically significant differences, regarding the prevalence of gender and the number of 
58 
previous (ipo)manic episode and a trend concerning the age at onset.  
Prevalence of female individuals was significantly greater among remitters than in the group of non-
remitters (95% vs 70%; p=0.03). It is difficult to explain this finding in relation to the current literature 
evidences. After early studies on clinical predictors to antidepressant response, that tends to indicate 
female gender as a risk factor for treatment resistance, current literature has become more critical of 
the relationship between female gender and treatment outcome39. Recent evidence suggest that gender 
has a role in predicting response to one antidepressant class versus another. For example, women may 
be less responsive than men to tricyclics and may respond preferentially to SSRIs or MAOIs241. It 
may be assumed that the differences in prevalence rates of depression for men and women have 
contributed to associate female gender with antidepressant treatment outcome in several studies as 
our one. However, in the few long term outcome studies on well-defined TRD patients, gender has 
generally not been found to be a predictor of outcome234. 
In our sample remitters had higher number of previous (ipo)manic episodes than non-remitters (1.20 
vs 0.37; p=0.05). This date, added to the trend of higher number of previous depressive episode, may 
delineate for remitters a clinical history marked by more evident cyclicity. It is plausible that such 
differences in previous clinical course are partly to be charged to the different diagnostic profile, since 
remitters had mainly diagnosis of MDD and BD type II and the more common diagnosis in the group 
of non-remitters was BD type I. However, if the comparison was limited to patients with bipolar 
depression (type I or II), the remitters’ mean number of previous (ipo)manic episodes was still 
significantly higher than in the group of non-remitters (2.5 vs 0.7; p=0.02), whilst the difference of 
mean number of previous depressive episodes tend to reduce. To our knowledge, there are no other 
data in literature that were directly comparable to our results on the relationship between number of 
previous episode and long term outcome of TRD. An indirect comparison could be made only with 
the findings of European multicentre study of GSRD70, which demonstrated the association of 
treatment resistance with history of recurrent episodes. 
Further relevant, although not statistically significant, difference between remitters and non-remitters 
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was reported in relation to mean age of illness onset. Illness course of non-remitters was on average 
marked by earlier onset (28.7 years) than in remitters (36 years; p=0.07).  Early age of depression 
onset was identified as a potential risk factor of treatment resistance in several studies. There is 
evidence15 that early onset is associated with a chronic course of illness, which tends to result in lower 
response rates and incomplete remission of symptoms. Recently, higher rates of treatment-resistant 
severity have found to be associated with longer lifetime duration of depressive illness, which is 
referred to an earlier age of onset4.  
As expected, during the 1-year follow up, remitters showed more significant improvement than non-
remitters. However, it is also to underline the reduction of symptom severity and the little increase of 
functioning levels also among non-remitters. 
Regarding drug treatment characteristics during the current episode, the only significant difference 
between the two groups was the assumption of SSRI at baseline, that resulted more frequent among 
non-remitters than remitters (80% vs 50%). If we take in account the remarkable, but not statistically 
significant, date on greater prescription of TCAs among remitters than non-remitters, we could 
conclude that in our sample the use of SSRIs may offer lower advantages of achieving remission than 
TCAs. Recent reviews245 of the relative efficacy of SSRIs and TCAs demonstrated substantial 
equivalence between the two classes, though these evidences are derived from clinical trials, that did 
not include patients with TRD.  
We compared also patients who developed the relapse of depressive symptoms after the remission 
(relapsed) with the remitters who continued to experience the resolution of episode at the endpoint 
(non-relapsed). The comparison did not show statistically significant differences in terms of 
sociodemographic and clinical features, except for the marital status, with none single among non-
relapsed patients (p=0.04). A trend to significant difference was also observed in depressive specifier, 
with neither case of psychotic depression among relapsed patients (p=0.08) and physical comorbidity, 
with higher rate of cardiovascular disease among relapsed patients than non-relapsed (p=0.07). 
Overall, these data are difficult to explain, because the small size of the sample. 
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The comparison between the two diagnostic subgroups of unipolar and bipolar TRD patients 
revealed several differences, such as the higher number of hospitalization among bipolar patients and 
longer duration of current episode in unipolar ones. These observations are consistent with the 
existing literature data. It is known from several studies4 that unipolar depression is characterized by 
a longer episode, with relevant likelihood of chronicity, which should be considered an important risk 
factor of TRD. On the other hand, depressed bipolar patients showed higher number of past episode 
that could result in higher number of hospitalization224. It has been also shown that bipolar depression 
is more frequently characterized than unipolar one by the presence of atypical features. In our sample, 
instead, symptomatological profile of bipolar patients’ current episode was marked by significant 
higher rate of melancholic specifier (75% vs 38.9%), while atypical features were more common 
among unipolar patients (50% vs 15.6%), although the difference was not statistically significant. 
This apparent discrepancy with literature could be related to our patients’ condition of treatment 
resistance. Overall, the evidence on clinical and treatment characteristics of TRD in bipolar disorder 
are still scanty; moreover, the few studies on the subject have not included direct comparisons with 
unipolar TRD. Though the melancholic subtype has been associated with treatment resistance, it 
should be considered that the data on this association were derived from studies including only 
unipolar patients70. The high prevalence of melancholic depression in our bipolar patients may be 
explained with the hesitation to prescribe TCAs, owing to the risk of inducing manic or mixed switch 
in this population. Nevertheless, melancholic depression may particularly benefit from the use of 
TCAs, as indicated by some literature evidence91. The frequent presence of atypical features among 
unipolar patients may be interpreted as a sign of subthreshold bipolarity, whose potential role on 
treatment resistance in unipolar depression was often emphasized by recent literature103-105. 
Concerning the characteristics of pharmacotherapy, the most interesting finding was the higher rate 
of assumption of benzodiazepines (BZD) among bipolar patients (81.2% vs 55.6%; p=0.05). In a 
recent study242 of the clinical variable of treatment resistance in bipolar disorder, Parker and Graham 
identified the frequent use of BZDs as a potential factors contributing to the Treatment-Resistant 
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Bipolar Disorder (TRBD). It can be assumed that also in our bipolar depressed patients, the more 
frequent assumption of BZD might play an important role in reducing likelihood of response to 
adequate treatments. Finally, it needs to remark the high rate of prescribed antidepressant drugs in 
the group of bipolar patients: 62.5% (SSRI/SNRIs) and 65.6% (TCAs) at baseline, 65.6% 
(SSRI/SNRIs) and 65.6% (TCAs) at endpoint. The debate about the effectiveness and safety of the 
use of antidepressant medication in bipolar depression is open for many years, but remain still far 
from resolved. Currently the only two drugs officially approved by FDA and EMEA are atypical 
antipsychotics as the quetiapine and the olanzapine in combination with fluoxetine (this latter does 
not still receive approbation by EMEA). The evidence from literature is still controversial, with 
randomized controlled data246 on the efficacy of antidepressant in combination with mood stabilizers 
that were contradicted by naturalistic study of effectiveness as the Systematic Treatment 
Enhancement Program for Bipolar Disorder (STEP-BD)243. Moreover, relatively few studies have 
examined the next step treatment strategies for resistant bipolar depression and no clear guidelines 
exist concerning what to do when the first approved therapies fail. The consequence is that, when a 
bipolar depressive episode occurs, in most cases clinicians prescribe any kind of drug from different 
classes, often comprising off-label medications, based not on available evidence, but rather on the 
personal experience. Our results seem then to confirm the discrepancy among data emerging from 




Some limitations of the study should be highlighted. First, the size of our sample was small for a 
detailed analysis of the various clinical and treatment variable associated to the follow-up outcome. 
Moreover, the sample was identified from a tertiary centre and is likely to represent the more severe 
spectrum of illness. Therefore, the findings may not fully generalize to treatment-resistant depression 
seen in other settings. Duration of follow up may appear short, if compared with other studies of long 
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term outcome of TRD, some of which have followed the patient up to a period of 84 months. 
However, unlike these studies, the period of evaluation after the enrolment was the same (1 year) for 






















The improvement of diagnostic approach and therapeutic strategies for Treatment-Resistant 
Depression (TRD) represents a real challenge for the research and the clinical practice, but also for 
the interest of world public health. As demonstrated in our study, TRD patients experience severe 
depressive symptoms for long period of illness, suffer from great social and working impairment and 
show a clinical history characterized by considerable recurrence, with frequent hospitalizations, high 
rates of psychiatric and physical comorbidity, great risk of suicide. Although the focusing of the 
researchers on this topic is growing, the number of studies, such as the present survey, which looks 
at the long-term outcome of TRD, is still scanty. On the hand, our results indicate the potential 
benefits of intensive, individualized, inpatient and multidisciplinary treatments, such as those offered 
by our tertiary centre, in a relevant proportion of cases. Nearly the forty percent of the sample 
achieved the remission during the follow up. This data highlights also the need to further investigate 
the role of certain therapeutic strategies, particularly antidepressant combinations and augmentation, 
which were found as the most used in the group of remitters. On the other hand, the finding of the 
60% of patients, who kept suffering from depression at the end of follow up, may be interpreted as 
further proof of the serious and chronic nature of TRD. The comparison between subgroups of 
patients, defined by the follow up outcome (remitters vs non-remitters), reported the association of 
female gender, higher number of previous (ipo)manic episodes and lower rate of assuming SSRI with 
the remission. These data should be considered as preliminary, since the small size of the sample. 
Even so, the higher number of previous (ipo)manic episode among remitters may suggest that a 
clinical history of cyclicity was predictive of better outcome in TRD, while the use of SSRIs in 
patients with long duration and multi-treatment refractory depressive episode may offer lower 
advantages than other medications, as indicated by the higher rate of prescribing SSRIs among non-
remitters. Finally, further interesting findings emerged from the comparison between unipolar and 
bipolar patients of our sample. The two groups were different for the symptomatologic profile of 
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current episode, with higher prevalence of the melancholic specifier among bipolar patients and 
greater rate of atypical features in the group of unipolar patients. Both these results seem to contradict 
literature data on differential traits between bipolar and unipolar depression, but the discrepancy 
should rely on the condition of treatment resistance, shared by our subgroups of patients. The finding 
of higher assumption of BZDs among bipolar patients may instead confirm the positive relationship 
between frequent use of BZDs and treatment resistant bipolar disorder, already seen in other studies. 
Further studies on larger populations of TRD patients followed-up for longer periods of time are 
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8. Tables and graphics  
Table I. Comparison between drug resistant major depressive patients with (Remitters) and 
without (NonRemitters) remission during 1-year follow-up 










Gender Male 10 (25) 1 (5) 9 (30) 4.68 0.03 
 Female  19(95) 21(70)   
Marital status Single 8(16) 1(5) 7(23.3) 4.63 0.99 
 Married 38(76) 16(80) 22(73.3)   
 Divorced/widower 4(8) 3(15) 1(3.3)   
Employment status Employed 18(36) 6(30) 12(40) 0.52 0.47 
 Unemployed  14(70) 18(60)   
Education Low/medium level 19(38) 6(30) 13(43.3) 0.90 0.34 
 High/medium 
level 
 14(70) 17(56.7)   
First degree family 
history 
Mood disorder 32(64) 13(65) 19(63.3) 0.01 0.90 
 Suicide 6(12) 3(15) 3(10) 0.28 0.59 
Principal diagnosis MDD 18(36) 8(40) 10(33.3) 1.48 0.47 
 BD I 20(40) 6(30) 14(46.7)   
 BD II 12(24) 6(30) 6 (20)   
Depressive specifier Psychotic 5(10) 3(15) 2(6.7) 1.64 0.44 
 Melancholic 31(62) 13(65) 18(60)   
 Atypical 14(28) 4(20) 10(33.3)   
Psychiatric 
comorbidity 




4(8) 1(5) 3(10) 0.40 0.52 
 Substance Use 
disorders 
5(10) 3(15) 2(6.7) 0.92 0.33 
 Others 2(4) 1(5.3) 1(3.3) 0.11 0.73 
Physical Illeness 
comorbidity 
Mellitus Diabetes 4(8) 2(10) 2(6.7) 0.18 0.67 
 Cardiovascular 
Disease 
17(34) 5(25) 12(40) 1.20 0.27 
 Tyroide Disease 7(14) 4(20) 3(10) 0.99 0.31 
 Others 13(26) 5(25) 8(26.7) 0.01 0.89 
Suicide Attempts Yes 11(22) 5(25) 6(20) 0.17 0.67 
Elettroconvulsive 
Therapy 
Yes 11(22) 4(20) 7(23.3) 0.29 0.58 
Current stage of 
resistance 
I 21(42) 10(50) 11(36.7) 3.00 0.39 
 II 15(30) 7(35) 8(26.7)   
 III 13(26) 3(15) 10(33.3)   
 IV 1(2) 0(0) 1(3.3)   
Medications at 
baseline 
SSRI/SNRI 30(60) 10(50) 20(66.7) 1.38 0.23 
 TCA 33(66) 11(55) 22(73.3) 1.79 0.18 
 Lithium 16(32) 6(30) 10(33.3) 0.06 0.80 
 SGA 11(22) 6(31.6) 5(16.7) 1.48 0.22 
 BDZ 36(72) 14(70) 22(73.3) 0.06 0.79 
 Others 43(86) 16(80) 27(90) 0.99 0.31 
Medications at 
endpoint 
SSRI/SNRI 34(68) 10(50) 24(80) 4.96 0.02 
 TCA 34(68) 16(80) 18(60) 2.20 0.13 
 Lithium 24(48) 11(55) 13(43.3) 0.65 0.41 
 SGA 14(28) 4(20) 10(34.5) 1.21 0.27 
 BDZ 24(68) 14(70) 20(66.7) 0.06 0.80 
 Others 45(90) 18(90) 27(90) 0.00 1.00 
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Table II. Comparison between drug resistant major depressive patients with (Remitters) and without (Non-










Age 53.46(11.80) 55.85(9.24) 51.87 (13.15) -1.17 0.24 
Age of onset 31.62(14.12) 36.00(12.92) 28.70(14.33) -1.83 0.07 
N° depressive episode 3.54(2.43) 4.25(3.19) 3.07(1.66) -1.71 0.09 
N° (ipo)manic episode 0.70(1.50) 1.20(2.16) 0.37(0.66) -1.97 0.05 
N°manic episode 0.44(0.86) 0.40(0.82) 0.47(0.90) 0.26 0.79 
N°mixed episode 0.46(0.78) 0.30(0.65) 0.57(0.85) 1.17 0.24 
Duration of current 
episode 
8.06(6.32) 6.75(5.11) 8.93(6.97) 1.20 0.23 
N°hospitalization 2.84(2.11) 2.75(2.63) 2.90(1.72) 0.24 0.80 
Current stage of 
resistance 
1.88(0.87) 1.65(0.74) 2.03(0.92) 1.54 0.12 
MADRS baseline 33.36(6.71) 32.35(7.05) 34.03(6.50) 0.86 0.39 
MADRS  endpoint 20(11.29) 9.65(6.31) 26.90(8.15) 7.98 0.00 
YMRS  baseline 2.14(2.19) 2.00(2.36) 2.23(2.11) 0.36 0.71 
YMRS  endpoint  1.96(2.97) 1.15(2.23) 2.52(3.31) 1.60 0.11 
CGI Severity baseline 4.76(1.02) 4.85(0.87) 4.70(1.11) -0.50 0.61 
CGI Severity endpoint 3.8(1.19) 3.10 (1.29) 4.27(0.86) 3.82 0.00 
CGI Improvement 
endpoint 
2.94(1.55) 1.75 (0.96) 3.73 (1.36) 5.62 0.00 
GAF baseline 49.28(7.44) 48.30 (8.88) 49.93(6.40) 0.75 0.45 













Table III. Comparison between remitted drug resistant major depressive patients with and without relapse 
during 1-year follow-up. Categorical variables. 










Gender Male 1 (5) 0 (0) 1 (5.9) 0.186 0.66 
 Female  3(100) 16(94.1)   
Marital status Single 1(5) 1(33.3) 0(0) 6.27 0.04 
 Married 16(80) 2(66.7) 14(82.4)   
 Divorced/widower 3(15) 0(0) 3(17.6)   
Employment status Employed 6(30) 1(33.3) 5(29.4) 0.52 0.47 
 Unemployed  2(66.7) 12(70.6)   
Education Low/medium level 6(30) 3(100) 3(17.6) 0.90 0.34 
 High/medium 
level 
 0(0) 14(82.4)   
First degree family 
history 
Mood disorder 13(65) 2(66.7) 11(64.7) 0.01 0.90 
 Suicide 3(15) 0(0) 3(17.6) 0.28 0.59 
Principal diagnosis MDD 8(40) 1(33.3) 7(41.2) 2.68 0.26 
 BD I 6(30) 0(0) 6(35.3)   
 BD II 6(30) 2(66.7) 4 (23.5)   
Depressive specifier Psychotic 3(15) 0(0) 3(17.6) 4.91 0.08 
 Melancholic 13(65) 1(33.3) 12(70.6)   
 Atypical 4(20) 2(66.7) 2(11.8)   
Psychiatric 
comorbidity 
AD 10(50) 1(33.3) 9(52.9) 0.39 0.53 
 OCD 1(5) 0(0) 1(5.9) 0.18 0.66 
 SA 3(15) 1(33.3) 2(11.8) 0.93 0.33 
 Others 1(5.3) 0(0) 1(5.3) 0.12 0.72 
Physical Illeness 
comorbidity 
Mellitus Diabetes 2(10) 1(33.3) 1(5.9) 2.13 0.14 
 Cardiovascular 
Disease 
5(25) 2(66.7) 3(17.6) 3.26 0.07 
 Tyroide Disease 4(20) 1(33.3) 3(17.6) 0.39 0.53 
 Others 5(25) 1(33.3) 4(23.5) 0.13 0.71 
Suicide Attempts Yes 5(25) 1(33.3) 4(23.5) 0.17 0.67 
Elettroconvulsive 
Therapy 
Yes 4(20) 0(0) 4(23.5) 0.29 0.58 
Augmentation trial Yes 7(35) 2(66.7) 5(29.4) 1.15 0.56 
Medications baseline SSRI 10(50) 1(33.3) 9(52.9) 0.39 0.53 
 TCA 11(55) 2(66.7) 9(52.9) 0.19 0.66 
 Lithium 6(30) 1(33.3) 5(29.4) 0.01 0.89 
 SGA 6(30) 1(33.3) 5(29.4) 0.05 0.94 
 BDZ 14(70) 1(33.3) 13(76.5) 2.26 0.13 
 Others 16(80) 2(66.7) 14(82.4) 0.39 0.53 
Medications 
endpoint 
SSRI/SNRI 10(50) 1(33.3) 9(52.9) 0.39 0.53 
 TCA 16(80) 2(66.7) 14(82.4) 0.39 0.53 
 Lithium 11(55) 2(66.7) 9(52.9) 0.19 0.66 
 SGA 4(20) 1(33.3) 3(17.6) 0.39 0.53 
 BDZ 14(70) 3(100) 11(64.7) 1.51 0.21 














Age 55.53(9.91) 57.67(4.04) -0.36 0.72 
Age of onset 35.71(13.66) 37.67(9.45) -0.2 0.81 
N° depressive episode 4.29(3.42) 4(1.73) 1.43 0.88 
N° (ipo)manic episode 1.18(2.29) 1.33(1.52) -0.13 0.91 
N°manic episode 0.47(0.87) 0.00(0.00) 0.91 0.37 
N°mixed episode 0.35(0.70) 0.00(0.00) 0.85 0.40 
Duration of current 
episode 
8.92(9.00) 5.33(0.57) -1.9 0.63 
N°hospitalization 2.29(2.59) 4(3.60) 1.01 0.32 
Current stage of 
resistance 
1.65(0.78) 1.67(0.57) -0.41 0.96 
MADRS at baseline 32.06(7.08) 34(8.18) -0.43 0.67 
MADRS at endpoint 8(5.14) 19(3.46) -3.52 0.00 
YMRS at baseline 2.06(2.51) 1.67(1.52) 0.25 0.79 
YMRS at endpoint  1.06(2.35) 1.67(1.52) -0.42 0.67 
CGI 1° item at baseline 4.88(0.85) 4.67(1.15) 0.38 0.70 
CGI 1° item at endpoint 3(1.36) 3.67(0.57) -0.81 0.42 
CGI 2° item at endpoint 1.65(0.93) 2.33(1.15) -1.14 0.26 
GAF at baseline 48.24(9.60) 48.67(3.21) -0.76 0.94 























Baseline Monotherapy 20 (40) 8 (40) 12 (40) 2.73 0.25 
 Combination 13 (26) 3 (15) 10 (30)   
 Augmentation 17 (34) 9 (45) 8 (26.7)   
Endpoint Monotherapy 6 (12.8) 3 (15) 3 (10) 0.52 0.76 
 Combination 20 (40) 7 (36.8) 13 (46.4)   
 Augmentation 20 (40) 9 (47.4) 12 (42.9)   
Remission Monotherapy  1 (5)    
 Combination  4 (20)    
 Augmentation  7 (35)    
 Switch  2(10)    
 Optimization  2 (10)    




































Table VI. Comparison between Bipolar and Unipolar Treatment Resistant Depression during 1-year follow-up 












Depressive specifier Psychotic 5(10) 3(9.4) 2(11.1) 0.04 0.84 
 Melancholic 31(62) 24(75) 7(38.9) 6.37 0.01 
 Atypical 14(28) 5(15.6) 9(50) 6.75 0.09 
Psychiatric 
comorbidity 




4(8) 2(6.1) 2(11.1) 0.37 0.54 
 Substance Use 
disorders 
5(10) 3(9.4) 2(11.1) 0.04 0.84 
 Others 2(4) 1(3.2) 1(5.6) 0.16 0.69 
Physical Illeness 
comorbidity 
Mellitus Diabetes 4(8) 3(9.4) 1(5.6) 0.23 0.63 
 Cardiovascular 
Disease 
17(34) 12(37.5) 5(27.8) 0.48 0.46 
 Tyroide Disease 7(14) 4(12.5) 3(16.7) 0.16 0.68 
 Others 13(26) 10(31.2) 3(16.7) 1.28 0.26 
Outcome Remission 20(40) 12(37.5) 8(44.4) 0.23 0.63 
 Relapse 13(26) 9(28) 4(22.2) 0.21 0.64 
Current stage of 
treatment resistance 
I 21(42) 16(50) 5(27.8) 3.90 0.27 
 II 15(30) 8(25) 7(38.9)   
 III 13(26) 8(25) 5(27.8)   
 IV 1(2) 0(0) 1(5.6)   
Medications at 
baseline 
SSRI 30(60) 20(62.5) 10(55.6) 0.23 0.63 
 TCA 33(66) 21(65.6) 12(66.7) 0.06 0.94 
 Lithium 16(32) 14(43.8) 2(11.1) 5.64 0.02 
 SGA 11(22) 9(28.1) 2(11.1) 1.94 0.29 
 BDZ 36(72) 26(81.2) 10(55.6) 3.77 0.05 
 Others 43(86) 28(87.5) 15(83.3) 0.17 0.68 
Medications at 
endpoint 
SSRI/SNRI 34(68) 21(65.6) 13(72.2) 0.23 0.63 
 TCA 34(68) 21(65.6) 13(72.2) 0.23 0.63 
 Lithium 24(48) 18(56.2) 6(33.3) 2.42 0.12 
 SGA 14(28) 13(41.9) 1(5.6) 7.38 0.07 
 BDZ 24(68) 22(68.8) 12(66.7) 0.02 0.88 
 Others 45(90) 29(90.6) 16 (88.9) 0.04 0.84 
Baseline type of 
treatment 
Monotherapy 20(40) 10(31.2) 10(55.6) 3.00 0.22 
 Combination 13(26) 9(28.1) 4(22.2)   
 Augmentation 17(34) 13(40.6) 4(22.2)   
Endpoint type of 
treatment 
Monotherapy 6(12.8) 2 (6.9) 4(22.2) 2.91 0.23 
 Combination 20(42.6) 12(41.4) 8(44.4)   




Table VII. Comparison between Bipolar and Unipolar Treatment Resistant Depression during 1-year follow-up. 







Age 53.88(9.91) 52.72(4.04) 0.33 0.74 
Age of onset 31.44(13.22) 31.94(16.03) -0.12 0.90 
N° depressive episode 3.69(1.89) 3.28(3.23) 0.56 0.57 
N° (ipo)maniac episode 1.09(1.76) 0.00(0.00) 2.61 0.01 
N°maniac episode 0.69(0.99) 0.00(0.00) 2.90 0.00 
N°mixed episode 0.72(0.88) 0.00(0.00) 3.42 0.00 
Duration of current 
episode 
6.31 (4.61) 11.17(7.80) -2.77 0.08 
N°hospitalization 3.28(2.51) 2.06(1.83) 2.03 0.04 
MADRS at baseline 33.56(7.28) 33.00(5.74) 0.28 0.78 
MADRS at endpoint 21.06(11.65) 18.11(10.69) 0.88 0.38 
YMRS at baseline 1.97(2.25) 2.44(2.12) -0.73 0.46 
YMRS at endpoint  2.32(3.52) 1.33(1.53) 1.12 0.26 
CGI 1° item at baseline 4.81(0.74) 4.67(1.41) 0.48 0.63 
CGI 1° item at endpoint 4.06(1.08) 3.33(1.23) 2.14 0.03 
CGI 2° item at endpoint 3.16(1.58) 2.56(1.46) 1.32 0.19 
GAF at baseline 50.34(5.67) 47.39(9.76) 1.35 0.18 











Stage I Failure of at least 1 adequate trial of 1 major class of antidepressants 
Stage II Failure of at least 2 adequate trials of at least 2 distinctly different 
classes of antidepressants 
Stage III Stage II resistance plus failure of an adequate trial of TCA 
Stage IV Stage III plus failure of an adequate trial of an MAOI 
 









The European Staging Method (Souery et al., 1999) 
 
 
Staging Definition  Duration of trial 
Non-responder Non-responder to 1 adequate 
trial of TCA, SSRI, IMAO, SNRI, 
ECT other antidepressant(s) 
6-8 weeks 
TRD Resistance to 1 or more adequate 
antidepressant trials 
TRD1: 12-16 weeks 
TRD2: 18-24 weeks 
TRD3: 24-32 weeks 
TRD4: 30-40 weeks 
TRD5: 36 weeks - 1 year 
Chronic resistant depression 
(CRD) 
Resistance to several 
antidepressant trials, including 
augmentation strategy 




















Massachusetts General Hospital Staging Method (Fava, 2003) 
 
Definition Score 
No response to each adequate (at least 6 weeks of an 
adequate dosage of an antidepressant) trial of 
marketed antidepressant generates an overall score 
of resistance 
1 point for trial 
Optimization of dose, optimization of duration, and 
augmentation or combination of each trial (based on 
the Massachusetts general Hospital or 
Antidepressant treatment Response Questionnaire) 
increase the overall score 
0.5 point per optimization or strategy 






Maudsley Staging Model (Fekadu et al., 2009) 
 
 
Parameter/Dimension Parameter specification Score 
Duration Acute (≤ 12 months) 
Subacute (13-24 months) 




Symptom severity (at baseline) Subsyndromal 
Syndromal 
       Mild 
       Moderate 
       Severe without psychosis 







Treatment failures antidepressant Level 1: 1-2 drugs 
Level 2: 3-4 drugs 
Level 3: 5-6 drugs 
Level 4: 7-10 drugs 



















Graphic 1. Comparison of principal psychiatric diagnosis between drug resistant patients with 




Graphic 2. Comparison of resistance stage according to Thase and Rush method between 


































Graphic 7. Comparison of depressive specifier between Bipolar and Unipolar treatment 























Graphic 10. Comparison of endpoint CGI Improvement score between Bipolar and Unipolar 
TRD patients. 
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